Page last updated: 2024-12-07

perindopril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Perindopril is an angiotensin-converting enzyme (ACE) inhibitor, a type of medication used to treat high blood pressure and heart failure. It is synthesized through a multi-step process involving various chemical reactions. Perindopril works by blocking the action of the ACE enzyme, which leads to the dilation of blood vessels and a decrease in blood pressure. This effect helps to reduce the workload of the heart and improve blood flow. Perindopril is a widely used medication, considered effective and safe for long-term treatment of hypertension and heart failure. It is studied extensively for its potential benefits in cardiovascular disease prevention, such as stroke and myocardial infarction. Research also explores its role in managing other conditions like diabetic nephropathy and chronic kidney disease.'

Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107807
CHEMBL ID1581
CHEBI ID8024
SCHEMBL ID16205
MeSH IDM0129811

Synonyms (95)

Synonym
BIDD:GT0786
smr001233453
MLS002154153
BRD-K92731339-227-02-3
s-90652
s-9490
prestarium
coverex
coverene cor
mcn-a-2833
coversum
sed-9490
dw-7950
(2s)-2-[(1s)-1-carbethoxybutylamino]-1-oxopropyl-(2s,3as,7as)-perhydroindole-2-carboxylic acid
perindoprilum [latin]
pirindopril
s 9490
(2s,3as,7as)-1-((s)-n-((s)-1-carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
mcn-a 2833
1h-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-
brn 4300272
11h-indole-2-carboxylic acid, octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))-
D03753
perindopril (usan/inn)
SPECTRUM_001948
1h-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-
82834-16-0
C07706
perindopril
(2s,3as,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid
DB00790
KBIO2_007630
KBIOSS_002502
KBIO2_005062
KBIOGR_001190
KBIO2_002494
KBIO3_002426
SPECTRUM2_001108
SPECTRUM4_000775
SPBIO_001216
SPECTRUM3_001683
BSPBIO_003206
SPECTRUM5_001689
ethyl n-{(2s)-1-[(2s,3as,7as)-2-carboxyoctahydro-1h-indol-1-yl]-1-oxopropan-2-yl}-l-norvalinate
CHEBI:8024 ,
perindoprilum
CHEMBL1581
(2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
HMS2098M04
(2s,3as,7as)-1-((s)-n-((s)-1-carboxybutyl)alanyl)hexahydro-2-indolinecarboxylicacid1-ethylester
dtxsid6023440 ,
dtxcid303440
cas-82834-16-0
tox21_113087
HMS2232M24
perindopril [usan:inn:ban]
y5gmk36kgy ,
unii-y5gmk36kgy
perindopril [vandf]
perindopril [mi]
perindopril [usan]
perindopril [mart.]
1h-indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2.alpha.,3a.beta.,7a.beta.))-
perindopril [who-dd]
(2s,3as,7as)-1-[(s)-n-[(s)-1-carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
perindopril [inn]
gtpl6367
AKOS025311315
CCG-221101
CS-1903
HY-B0130
SCHEMBL16205
NCGC00274070-01
tox21_113087_1
(2s,3as,7as)-1-{(2s)-2-[(1s)-1-(ethoxycarbonyl)butylamino]propionyl}octahydro-1h-indole-2-carboxylic acid
IPVQLZZIHOAWMC-QXKUPLGCSA-N
AB00918721_06
(2s,3as,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1h-indole-2-carboxylic acid
J-523913
sr-01000841817
SR-01000841817-2
(2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-2-pent-yl]amino]propanoyl]-octahydro-1h-indole-2-carboxylic acid
SBI-0206736.P001
HMS3715M04
Q277785
bdbm50493988
BRD-K92731339-227-03-1
(2s,3as,7as)-1-((s)-2-(((s)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
EX-A6377
EN300-7481397
(2s,3as,7as)-1-((2s)-2-(((2s)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)octahydro-1h-indole-2-carboxylic acid
perindoprilum (latin)
ethyl n-((2s)-1-((2s,3as,7as)-2-carboxyoctahydro-1h-indol-1-yl)-1-oxopropan-2-yl)-l-norvalinate
c09aa04
perindopril (mart.)

Research Excerpts

Overview

Perindopril erbumine (PE) is a BCS (Biopharmaceutics Classification System) class 3 drug with high solubility and low permeability. It is an effective and safe treatment for the prevention of AF recurrence after radiofrequency catheter ablation.

ExcerptReferenceRelevance
"Perindopril is a long acting ACE inhibitor with a 24- hour lasting effect. "( [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form].
Václavík, J, 2013
)
2.74
"Perindopril erbumine (PE) is a BCS (Biopharmaceutics Classification System) class 3 drug with high solubility and low permeability. "( Development and in vitro/in vivo evaluation of immediate release perindopril tablets.
İnce, İ; Karasulu, E; Ölçer, A; Ölçer, M, 2015
)
2.1
"Perindopril is an effective and safe treatment for the prevention of AF recurrence after radiofrequency catheter ablation. "( Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience.
Dong, F; Li, H; Qiu, Y; Shang, Y; Wang, Q; Wang, Z; Zheng, L; Zhou, D, 2016
)
3.32
"Perindopril is an effective antihypertensive medication. "( Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
Drzewoski, J; Gaciong, Z; Gasowski, J; Grodzicki, T; Kabat, M; Kłoś, J; Wilkins, A, 2010
)
2.07
"Perindopril/indapamide is an effective and safe antihypertensive treatment in everyday medical practice."( Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice.
Farsang, C, 2013
)
1.35
"Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. "( Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari, R, 2005
)
2
"Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. "( Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Campo, G; Ceconi, C; Ferrari, R; Gardini, E; Notarstefano, P; Pasanisi, G, 2005
)
2.05
"Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. "( Perindopril.
Alfakih, K; Hall, AS, 2006
)
3.22
"Perindopril (Coversyl) is a prodrug ester of perindoprilat, an ACE inhibitor. "( Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran, MP; McCormack, PL; Simpson, D, 2006
)
3.22
"Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. "( [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Ciliberti, P; Graziosi, M; Rapezzi, C; Riva, L, 2005
)
1.99
"Perindopril is a third-generation long acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin."( Role of perindopril in the prevention of stroke.
Papadopoulos, DP; Votteas, V, 2006
)
1.49
"Perindopril is a significant contribution to the spectrum of drugs used in the treatment of hypertension because of its 24-hour effectiveness and very good tolerance."( [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study].
Fedelesová, V; Uhlír, O; Widimský, J, 1995
)
1.28
"Perindopril is a third generation converting enzyme inhibitor that produces profound and prolonged angiotensin-converting enzyme (ACE) inhibition (24 h after a single dose)."( Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure.
Sami, MH, 1994
)
1.31
"Perindopril is a long acting angiotensin-converting enzyme inhibitor with a perhydroindole group and no sulphydryl radical. "( Clinical review of perindopril in the treatment of hypertension.
Antony, I; Lerebours, G, 1994
)
2.06
"Perindopril is a well tolerated ACE inhibitor that is significantly better than captopril (in terms of response rates) in the treatment of hypertension, and as effective as other ACE inhibitors. "( Perindopril: an updated review of its use in hypertension.
Hurst, M; Jarvis, B, 2001
)
3.2
"Perindopril erbumine is a once-daily angiotensin-converting enzyme (ACE) inhibitor that effectively lowers systolic and diastolic blood pressure (BP) in patients with mild-to-moderate hypertension. "( Dosage considerations with perindopril for systemic hypertension.
Sica, DA, 2001
)
2.05
"Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. "( Perindopril: in congestive heart failure.
Goa, KL; Noble, S; Simpson, D, 2002
)
3.2
"5. Perindopril is an effective antihypertensive agent with an acceptable side-effect profile in people with hypertension."( Clinical efficacy of perindopril in hypertension.
Anderson, A; Morgan, T, 1992
)
1.12
"Perindopril is a non-sulphydryl angiotensin converting enzyme (ACE) inhibitor which requires hydrolysis to its active metabolite, perindoprilat, to produce its effects. "( The pharmacokinetics of perindopril in patients with liver cirrhosis.
Funck-Brentano, C; Grangé, JD; Jaillon, P; Midavaine, M; Resplandy, G; Thiollet, M, 1992
)
2.03
"1 Perindopril is a prodrug which is hydrolysed in vivo to the active metabolite perindoprilat, an angiotensin-converting enzyme inhibitor. "( Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
De Broe, ME; Genissel, PM; Thomas, JR; Verpooten, GA, 1991
)
1.29
"Perindopril is a long acting angiotensin converting enzyme (ACE) inhibitor, which displays similar pharmacodynamic properties to other agents in this class. "( Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.
Fitton, A; Todd, PA, 1991
)
3.17
"Perindopril (P) is a prodrug whose active metabolite perindoprilat (PT) is an antihypertensive agent which acts by inhibition of angiotensin-converting enzyme (ACE). "( Radioimmunoassay of a new angiotensin-converting enzyme inhibitor (perindopril) in human plasma and urine: advantages of coupling anion-exchange column chromatography with radioimmunoassay.
Bernheim, C; Cailla, H; De Veyrac, B; Delaage, M; Devissaguet, M; Doucet, L, 1990
)
1.96
"Perindopril is a non-sulphydryl, pro-drug, ACE inhibitor. "( Clinical pharmacology of perindopril.
Lees, KR, 1990
)
2.03
"Perindopril is an orally active non-thiol angiotensin-converting enzyme (ACE) inhibitor that is hydrolysed by esterases to a biologically active diacid metabolite. "( Vascular haemodynamic effects of perindopril in essential hypertension.
Littler, W, 1990
)
2
"Perindopril is an orally active, non-thiol angiotensin-converting enzyme (ACE) inhibitor, which in doses of 4 to 8mg is effective in the control of essential hypertension. "( Perindopril. A review of its pharmacokinetics and clinical pharmacology.
Lees, KR; Macfadyen, RJ; Reid, JL, 1990
)
3.16
"Perindopril is a new inhibitor of converting enzyme activity with a prolonged half-life. "( The effect of perindopril on blood pressure in humans on different sodium intakes.
Anderson, A; Morgan, T; Murphy, J; Nowson, C; Wilson, D, 1987
)
2.08
"Perindopril appears to be a well tolerated inhibitor of plasma angiotensin converting enzyme, with predictable effects on the renin angiotensin system and blood pressure."( Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man.
Lees, KR; Reid, JL, 1987
)
1.26
"Perindopril is a new angiotensin converting enzyme (ACE) inhibitor which is activated after hydrolysis in vivo to a diacid (S9780). "( Perindopril, a new angiotensin converting enzyme inhibitor--clinical pharmacological studies in healthy subjects.
Lees, KR; Perret, L; Reid, JL, 1987
)
3.16

Effects

Perindopril has a similar adverse event profile to that of other ACE inhibitors. cough is the most common event reported during treatment, and is also the mostcommon adverse event responsible for treatment withdrawal.

Perindopril is a long-acting lipophilic angiotensin-converting enzyme inhibitor. It has been used in the clinical practice for more than 25 years. cough is the most common event reported during treatment, and is also the mostcommon adverse event responsible for treatment withdrawal.

ExcerptReferenceRelevance
"Perindopril has a positive safety and tolerability profile."( Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts, JJ; Ferrari, R; Simoons, ML, 2009
)
1.34
"Perindopril has a well established role in the treatment of patients with hypertension or heart failure."( Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran, MP; McCormack, PL; Simpson, D, 2006
)
2.5
"Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal."( Perindopril: an updated review of its use in hypertension.
Hurst, M; Jarvis, B, 2001
)
2.47
"Perindopril, which has been used in the clinical practice for more than 25 years, is a long-acting lipophilic angiotensin-converting enzyme inhibitor with a once-daily dosage schedule and a high affinity to tissue-converting enzyme."( Perindopril: a long-term certainty in treating hypertension.
Souček, M, 2021
)
2.79
"Perindopril has proven efficacy in the prevention of cardiovascular events and mortality in CAD patients, while amlodipine is widely used in the symptomatic management of CAD."( Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.
Ferrari, R, 2008
)
1.28
"Perindopril has a positive safety and tolerability profile."( Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
Brugts, JJ; Ferrari, R; Simoons, ML, 2009
)
1.34
"Perindopril has good effects in decreasing AER in normotensive early diabetic nephropathy and in protecting the renal function."( [The effect of perindopril in treatment of early diabetic nephropathy with normal blood pressure and microalbuminuria].
Hu, G; Li, Y; Liao, Z; Yao, B; Zhang, Y, 2001
)
2.11
"Perindopril has a well established role in the treatment of patients with hypertension or heart failure."( Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran, MP; McCormack, PL; Simpson, D, 2006
)
2.5
"Perindopril has a similar adverse event profile to that of other ACE inhibitors; cough is the most common event reported during treatment, and is also the most common adverse event responsible for treatment withdrawal."( Perindopril: an updated review of its use in hypertension.
Hurst, M; Jarvis, B, 2001
)
2.47
"Perindopril has no negative effects on lipids in patients with hyperlipidemia or on glycemic control in patients with type 2 diabetes mellitus, and it reduces proteinuria in patients with renal disease."( Safety profile of perindopril.
Clark, LT, 2001
)
1.37
"Perindopril has been studied in groups of normal young and elderly subjects, in patients with hepatic cirrhosis and in hypertensive patients. "( Pharmacokinetics of perindopril: therapeutic consequences.
Hughes, DM; Lees, KR; McNeill, CA; Reid, JL, 1989
)
2.04
"Perindopril has been studied in groups of normal young and elderly subjects, in patients with hepatic cirrhosis and in hypertensive patients. "( Pharmacokinetics of perindopril: therapeutic consequences.
Hughes, DM; Lees, KR; McNeill, CA; Reid, JL, 1989
)
2.04

Actions

Perindopril did not increase muscle strength or mass in any polymorphism group relative to placebo. The natriuretic effect may be related to changes in renal hemodynamics inducing a decreased sodium reabsorption in the proximal tubule.

ExcerptReferenceRelevance
"Perindopril did not increase muscle strength or mass in any polymorphism group relative to placebo."( ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.
Achison, M; Adamson, S; Akpan, A; Aspray, T; Avenell, A; Band, MM; Bashir, T; Burton, LA; Cvoro, V; Donnan, PT; Duncan, GW; George, J; Gordon, AL; Gregson, CL; Hapca, A; Hume, C; Jackson, TA; Kemp, PR; Kerr, S; Kilgour, A; Masud, T; McKenzie, A; McKenzie, E; Patel, H; Pilvinyte, K; Roberts, HC; Rossios, C; Sayer, AA; Smith, KT; Soiza, RL; Steves, CJ; Struthers, AD; Tiwari, D; Whitney, J; Witham, MD, 2023
)
1.63
"Perindopril plays an essential role in AF induction and maintenance."( Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience.
Dong, F; Li, H; Qiu, Y; Shang, Y; Wang, Q; Wang, Z; Zheng, L; Zhou, D, 2016
)
2.6
"The perindopril-induced increase in brachial artery flow was related (a) at the low dose to the sole arteriolar and (b) at the two highest doses to both arteriolar and large vessels dilatation."( [Peripheral hemodynamic and biological effects of perindopril in the healthy subject. Dose-effect relationship].
Desmichels, D; Giudicelli, JF; Richer, C; Thuillez, C, 1986
)
1.01
"Perindopril produced an increase in natriuresis after the first intake and at D5; this natriuretic effect may be related to the changes in renal hemodynamics inducing a decreased sodium reabsorption in the proximal tubule."( [The effects of inhibition of converting enzyme by perindopril on renal hemodynamics and natriuresis in essential arterial hypertension].
Ayad, M; Barrou, Z; Chaignon, M; Guédon, J, 1988
)
1.25

Treatment

Perindopril/indapamide treatment has been shown to reduce blood pressure and to have significant beneficial effects on arterial distensibility, kidney structure and function. The study showed an improvement of endothelial function associated with the 12-month perindoprill therapy in patients with HFpEF and HFiEF.

ExcerptReferenceRelevance
"Perindopril treatment (1 mg/kg/day) was administered to a subset of WKY rats commencing at week 8 of the 20 week HFHC feeding period."( Perindopril prevents development of obesity and hypertension in middle aged diet-induced obese rat models of metabolic syndrome.
Batacan, R; Connolly, K; Fenning, A; Jackson, D; Vella, R, 2023
)
3.07
"Perindopril treatment prevented the development of obesity and hypertension in WKY-HFHC."( Perindopril prevents development of obesity and hypertension in middle aged diet-induced obese rat models of metabolic syndrome.
Batacan, R; Connolly, K; Fenning, A; Jackson, D; Vella, R, 2023
)
3.07
"The perindopril treatment was associated with increased density of the capillary network at rest (р=0.008) and in tests with venous occlusion (р=0.003) and reactive hyperemia (р=0.0003).Conclusion      The study showed an improvement of endothelial function associated with the 12-month perindopril therapy in patients with HFpEF and HFiEF."( [Positive Effects of Perindopril on Microvascular Vessels in Patients With Chronic Heart Failure].
Belenkov, YN; Danilogorskaya, YA; Ilgisonis, IS; Khabarova, NV; Kozhevnikova, MV; P, EV; Safonova, JI; Shchendrygina, AA; Zektser, VY; Zheleznykh, EA, 2020
)
1.36
"Perindopril/indapamide treatment has been shown to reduce blood pressure and to have significant beneficial effects on arterial distensibility, kidney structure and function, and endothelial function. "( Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes.
Lévy, BI; Taddei, S, 2018
)
2.17
"Perindopril treatment showed a significant restoration in the pathological alterations histologically and biochemically, which are provoked by CP administration."( Perindopril regulates the inflammatory mediators, NF-κB/TNF-α/IL-6, and apoptosis in cisplatin-induced renal dysfunction.
Abd El-Ghany, AA; Hassan, MIA; Shalkami, AS, 2018
)
2.64
"The perindopril treatment (6 mg/kg BW), starting 4 weeks after administering STZ, resulted in a significant improvement of all symptoms and signs of DN, significantly lowering the values of BUN and serum creatinine, albuminuria and diuresis."( Perindopril treatment in streptozotocin induced diabetic nephropaty.
Jakjovski, K; Labacevski, N; Petrusevska, G; Trojacanec, J; Trojacanec, P; Zafirov, D; Zdravkovski, P, 2013
)
2.31
"Perindopril treatment significantly decreased the frequency and geometric mean titre in patients positive for anti-AT1-AR, even to complete ablation. "( Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor.
Chen, J; Du, Q; Hakonarson, H; Hu, A; Liu, J; Wang, H; Wang, X; Wu, J; Xu, L; Zhang, J; Zhang, L; Zhang, Z, 2013
)
3.28
"Both perindopril and losartan treatment significantly reduced the pulmonary fibrosis score, content of hydroxyproline, protein expression of TGF-beta1, DNA binding activity of NF-kappaB and MMP-2, 9 activity, and increased cytoplasmic protein expression of IkappaBalpha. "( [Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats].
Cai, SX; Cheng, YX; Li, X; Meng, Y; Tong, WC, 2008
)
1.77
"Perindopril treatment significantly reduced PWD in hypertensive patients."( Perindopril decreases P wave dispersion in patients with stage 1 hypertension.
Fak, AS; Ozben, B; Papila-Topal, N; Sumerkan, M; Tanrikulu, AM; Toprak, A, 2009
)
3.24
"Perindopril treatment was tolerated well."( The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans.
De La Garza, R; Grasing, K; Newton, TF, 2010
)
1.34
"Perindopril treatment reduced resistin levels, while enalapril only tended to decrease its content."( The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease.
Krysiak, R; Marek, B; Okopień, B; Sierant, M,
)
1.21
"Perindopril treatment not only attenuated the tubulointerstitial injury and the macrophages infiltration but also reduced the overexpression of SR-A mRNA in diabetic rats."( Perindopril attenuates renal tubulointerstitium injury by inhibiting scavenger receptor A over-expression in diabetic rats.
Hu, F; Liu, L; Shu, XC; Sun, HL; Sun, L; Sun, Y; Wen, JH; Yang, Q; Yin, DC; Zeng, YJ, 2012
)
2.54
"Perindopril treatment inhibited lymphocyte cytokine release and systemic inflammation, while the effect of enalapril was insignificant."( Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
Krysiak, R; Okopień, B, 2011
)
1.09
"In perindopril-treated rats, systolic and diastolic blood pressure decreased after treatment (92+/-4/65+/-2 mm Hg)."( Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts.
Kimura, S; Kohno, M; Mizushige, K; Murakami, K; Noma, T; Tsuji, T, 2002
)
2.27
"Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3.0 [95% CI -5.6, -0.4], P=0.012; systolic BP -1.5 [95% CI -3.0, -0.1] diastolic BP P=0.019) and AER -42% (95% CI -50%, -33%) versus -27% (95% CI -37%, -16%) with enalapril."( Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
De Leeuw, PW; Erdogan, G; Halimi, S; Hamani, A; Hess, B; Jermendy, G; Luger, A; Mechmeche, R; Mogensen, CE; Nolan, J; Ribeiro, A; Ritz, E; Ruilope, L; Rull, J; Sanchez, R; Sareli, P; Scheen, A; Sirotiakova, J; Taton, J; Thomas, SM; Viberti, G; Widimsky, J, 2003
)
1.37
"Perindopril treatment produced improvements (p<0.05) in all indices, whereas aminoguanidine therapy produced some improvement in blood glucose and water intake."( ACE inhibition salvages the visual loss caused by diabetes.
Armitage, JA; Bui, BV; Cooper, ME; Tolcos, M; Vingrys, AJ, 2003
)
1.04
"Perindopril treatment was associated with normalization of both capillary endothelial cell density and glomerular VEGF mRNA."( Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model.
Cox, AJ; Gilbert, RE; Hepper, C; Kelly, DJ; Wu, LL, 2003
)
1.04
"Perindopril treatment significantly reduced mean fibrosis score, messenger RNA and protein levels of AT1 receptor, protein levels of TGF-beta1 and PDGF-BB, Serum levels of HA and LN, and MMP-2 activity."( [Perindopril attenuates the progression of CCl4-inducing rat hepatic fibrosis].
Li, X; Meng, Y; Wu, PS; Yang, XS; Zhang, ZS; Zou, JL, 2004
)
1.96
"Perindopril/indapamide treatment led already after 4 weeks to a significant blood (BP) reduction with most prominent BP differences at the end of the study (sitting BP 130 +/- 10/84 +/- 6 mm Hg vs. "( [Evaluation of the antihypertensive efficacy and tolerability of fixed very low-dose perindopril/indapamid combination in patients with mild to moderate hypertension. Results of a Czech and Slovak multicentric study].
Fedelesová, V; Widimský, J, 2004
)
1.99
"Perindopril/indapamide treatment resulted in the improvement of diastolic function and in the regression of the left ventricle mass."( [Evaluation of the antihypertensive efficacy and tolerability of fixed very low-dose perindopril/indapamid combination in patients with mild to moderate hypertension. Results of a Czech and Slovak multicentric study].
Fedelesová, V; Widimský, J, 2004
)
1.27
"In perindopril-treated diabetic rats, staining of type IV collagen and laminin was less strong when compared with untreated diabetic rats."( Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes.
Erensoy, N; Hatemi, H; Oztürk, M; Tunçdemir, M; Uysal, O; Yilmazer, S, 2004
)
0.84
"Perindoprilat treatment also significantly suppressed angiotensin II production in vitro."( Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells.
Ito, A; Komune, S; Kuratomi, Y; Masuda, M; Nakagawa, T; Nakashima, T; Yasumatsu, R, 2004
)
1.29
"Perindopril treatment is effective and well tolerated in elderly patients with hypertension."( Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
Batchelor, A; Cohn, JN; Guo, W; Julius, S; Lagast, H; Neutel, JM; Shen, Y; Turlapaty, P; Weber, MA, 2004
)
2.07
"Perindopril treatment was associated with a non-significant reduction in the primary endpoint in the diabetic population, 12.6 vs."( The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Bertrand, ME; Daly, CA; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML, 2005
)
1.41
"Perindopril treatment significantly reduced mean fibrosis score, protein levels of AT1R, TGF-beta1 and PDGF-BB, serum levels of HA and LN, and the activity of MMP-2,9."( ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9.
Cai, SX; Li, X; Meng, Y; Mi, LF; Yang, XS, 2005
)
1.05
"Perindopril treatment partially prevented cardiac dysfunction and left ventricular remodeling as indicated by the above indices."( [Effects of perindopril on left ventricular remodeling and myocardial osteopontin expression in rats with myocardial infarction].
Wang, JF; Wang, MH; Zhang, YL; Zhou, SX, 2006
)
1.43
"Perindopril treatment can significantly inhibit left ventricular remodeling and myocardium osteopontin expression in rats with MI."( [Effects of perindopril on left ventricular remodeling and myocardial osteopontin expression in rats with myocardial infarction].
Wang, JF; Wang, MH; Zhang, YL; Zhou, SX, 2006
)
2.16
"Perindopril-based treatment reduced the risk of major vascular events by 30% and stroke by 35% among subjects with CKD, and the absolute effects of treatment were 1.7-fold greater for those with CKD than for those without."( Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
Arima, H; Cass, A; Chalmers, J; Gallagher, M; Jardine, M; Macmahon, S; Neal, B; Ninomiya, T; Perkovic, V, 2007
)
1.3
"Perindopril/indapamide treatment reduced 24-hour and daytime systolic BP (SBP) and pulse pressure (PP) significantly more than enalapril treatment (p < 0.01)."( Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy.
Asmar, R; De Leeuws, PW; Garcia-Puig, J; Gosse, P; Karpov, YA; Magometschniggs, D; Matos, L; Schmieder, R, 2007
)
1.27
"Perindopril treatment completely removed hypertension."( Angiotensin converting enzyme inhibition from birth reduces body weight and body fat in Sprague-Dawley rats.
Begg, DP; Egan, GF; Jayasooriya, AP; Lie, F; Mathai, ML; Sinclair, AJ; Wark, JD; Weisinger, HS; Weisinger, RS, 2008
)
1.07
"Perindopril treatment reduced plasma angiotensin-converting enzyme (ACE) activity by 88% but did not significantly alter arterial blood pressure or heart rate."( Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries.
Dusting, GJ; Hickey, H; Hyland, R; Makdissi, M, 1995
)
1.01
"Perindopril treatment did not significantly modify the increased pulmonary capillary wedge and mean circulatory filling pressures, reduced total vascular compliance or total vascular capacitance associated with the volume load and acute RRVP. "( Effect of perindopril in pacing-induced canine models of acute and chronic heart failure.
Ogilvie, RI; Zborowska-Sluis, D, 1995
)
2.14
"Perindopril treatment also prevented development of cardiac hypertrophy in SHR."( Beta-adrenoceptor subtypes in the atrioventricular conducting system and myocardium of spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibition by perindopril.
Matthews, JM; Molenaar, P; Summers, RJ, 1994
)
1.2
"Perindopril treatment resulted in the normalization of SBP after 2 weeks of treatment. "( Perindopril treatment prolonged the lifespan of spontaneously hypertensive rats.
Delaney, KH; Lee, RM; Lu, M, 1995
)
3.18
"Perindopril treatment caused an increase in small artery diameter (231 +/- 14 to 274 +/- 13 microns, P < .05) and a reduction in the ratio of media thickness to lumen diameter (7.94 +/- 0.65% to 5.96 +/- 0.42%, P < .05), whereas atenolol had no effect (246 +/- 14 to 231 +/- 13 microns and 7.14 +/- 0.47% to 6.79 +/- 0.45%, respectively)."( Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.
Aalkjaer, C; Cooper, A; Heagerty, AM; Mulvany, MJ; Stephens, N; Thybo, NK, 1995
)
1.01
"Perindopril treatment from 6 to 9 mo reversed cardiac hypertrophy and the relative decrease in SERCA 2 mRNA level."( Sarcoplasmic reticulum Ca2+ pumps in heart and diaphragm of cardiomyopathic hamster: effects of perindopril.
Anger, M; Chemla, D; Desche, P; Lambert, F; Lecarpentier, Y; Lompre, AM; Scalbert, E, 1995
)
1.23
"Perindopril treatment was started at 2 mg, increasing to 4 mg once daily after 2 weeks if supine systolic blood pressure remained > 100 mm Hg."( Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Results of a long-term open study in 320 patients.
Antony, I; Desche, P; Lerebours, G; Robert, S; Violet, I; Weber, C, 1993
)
1.35
"Perindopril treatment dose-dependently reduced both cardiac and vascular hypertrophy but to different extents."( Relationship between cardiovascular hypertrophy and cardiac baroreflex function in spontaneously hypertensive and stroke-prone rats.
Head, GA; Minami, N, 1993
)
1.01
"Perindopril treatment normalized blood pressure, prevented wall morphology alterations, and improved function but had no effect on VSMC disorganization."( Confocal microscopic characterization of a lesion in a cerebral vessel of the stroke-prone spontaneously hypertensive rat.
Arribas, SM; Daly, CJ; Dominiczak, AF; Gordon, JF; McGrath, JC, 1996
)
1.02
"In perindopril-treated LH, ANG II produced a greater reduction in renal blood flow, glomerular filtration rate, and urinary sodium excretion that was not significantly modified by blockade of thromboxane A2-prostaglandin H2 receptors."( In the Lyon hypertensive rat, renal function alterations are angiotensin II dependent.
Benzoni, D; Liu, KL; Sassard, J, 1996
)
0.81
"Perindopril treatment reduced plasma angiotensin converting enzyme (ACE) activity by 88%, but did not significantly alter arterial blood pressure or heart rate."( Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits.
Dusting, GJ; Hickey, H; Hyland, R; Makdissi, M; Wilks, D, 1996
)
2.46
"Perindopril treatment for one week produced a dose-dependent hypotensive effect with the threshold dose, 0.06 mg kg-1 day-1, producing a 6.5 +/- 1.8 mmHg fall in MAP."( Short-term and long-term cardiovascular actions of different doses of perindopril in the rabbit.
Campbell, GR; Campbell, JH; Fennessy, PA; Godwin, S; Head, GA,
)
1.09
"Perindopril treatment shifted the membrane potential value to -13.45 +/- 0.99 mV when measured after a single dose of the drug, or even depolarized the membrane after 7 days of therapy -4.95 +/- 0.73 mV."( Effect of perindopril therapy on fluidity and potential of erythrocyte membrane from individuals with coronary heart disease.
Bryszewska, M; Buczyński, A; Kedziora, J; Koter, M; Leyko, W; Piasecka, A; Tkaczewski, W, 1997
)
1.42
"Perindopril and losartan treatment of SHR and WKY rats led to a heterogeneous response in the vasculature, resulting in a reduction in perfusion pressures at maximum dilatation and constriction in the hindquarter vasculature but no significant change in medial cross-sectional area of small mesenteric arteries. "( Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats.
Black, MJ; Bobik, A; Kanellakis, P, 1997
)
1.74
"In perindopril-treated LH rats, a 4-wk infusion of ANG II (200 ng.kg-1.min-1) but not of NE (1,000 ng.kg-1.min-1) restored hypertension, mimicked the hemodynamic alterations seen in untreated LH rats, and produced a brief sodium retention."( Pivotal role of the renin-angiotensin system in Lyon hypertensive rats.
Lantelme, P; Lo, M; Luttenauer, L; Sassard, J, 1997
)
0.81
"Perindopril in treatment hypertension effectively reduces the level of blood pressure (systolic, diastolic and mean) without any effect on heart rate. "( [Perindopril in monotherapy of primary hypertension--6 month observation].
Cholewa, M; Cwetsch, A; Kamiński, G; Kubik, L; Skrobowski, A, 1997
)
2.65
"The perindopril-treated kidneys began filtering at a significantly lower threshold perfusion pressure than nontreated controls (P<.001)."( Perindopril treatment affects both preglomerular renal vascular lumen dimensions and in vivo responsiveness to vasoconstrictors in spontaneously hypertensive rats.
Anderson, WP; Bergström, G; Johansson, I; Kett, MM; Stevenson, KM, 1998
)
2.22
"Perindopril treatment preserves the myogenic response of MCA in SHRSP and prevents the stroke development in these animals."( Prevention of stroke and preservation of the functions of cerebral arteries by treatment with perindopril in stroke-prone spontaneously hypertensive rats.
Lee, RM; Smeda, JS; Wang, H, 1998
)
1.24
"Perindopril treatment for 4 weeks reduced mean cardiac region weights but did not affect beta-ar density in any cardiac region in either sham-operated or MI rats."( Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril.
Gu, XH; Kompa, AR; Summers, RJ, 1998
)
1.25
"Perindopril treatment for 6-week (SHR-S) and 9-week (SHR-L) durations maintained blood pressure at normotensive levels in both groups."( ANP and bradycardic reflexes in hypertensive rats: influence of cardiac hypertrophy.
Head, GA; Thomas, CJ; Woods, RL, 1998
)
1.02
"Perindopril treatment almost abolished plasma angiotensin converting enzyme activity, whereas L-158,809 treatment had no effect."( Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension.
Gillies, LK; Lee, RM; Werstiuk, ES, 1998
)
1.02
"Perindopril treatment also effectively prevented the development of vascular hypertrophy; however, treatment with hydralazine and hydrochlorothiazide was not as effective despite equivalent blood pressure reduction."( Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27.
Brosnan, MJ; Clark, JS; Devlin, AM; Dominiczak, AF; Mullins, JJ, 1999
)
1.02
"The perindopril-treatment may prevent these changes in SHRSP."( Effect of chronic treatment with perindopril on endothelium-dependent relaxation of aorta and carotid artery in SHRSP.
Matsuda, K; Noguchi, K; Ozaki, M; Sekiguchi, F; Shibano, T; Shimamura, K; Sunano, S; Tanaka, M; Yamamoto, K, 2000
)
1.07
"Perindoprilat treatment also significantly inhibited VEGF mRNA expression in BNL-HCC cells in vitro."( The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
Fukui, H; Ikenaka, Y; Kawata, M; Kuriyama, S; Nakatani, T; Noguchi, R; Tsujinoue, H; Yoshii, J; Yoshiji, H, 2001
)
1.29
"Perindopril treatment produces a greater decrease in AI than continuation with previous therapy, but this can be largely explained by hemodynamic changes rather than direct arterial effects."( Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension.
Dart, AM; McGrath, B; Reid, CM, 2001
)
1.03
"Perindopril treatment inhibited the development of atherosclerotic lesions and diabetes-induced ACE, connective tissue growth factor, and vascular cell adhesion molecule-1 overexpression in the aorta."( Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Allen, TJ; Burns, WC; Candido, R; Cao, Z; Cooper, ME; Dilley, RJ; Jandeleit-Dahm, KA; Nesteroff, SP; Twigg, SM, 2002
)
1.04
"In perindopril-treated guinea-pigs, the activity of angiotensin-converting enzyme was decreased by 90% with simultaneous increases in plasma renin activity and angiotensin I concentration; aldosterone and vasopressin levels, blood pressure and heart rate were not modified."( Endocrine and hemodynamic responses to dopamine infusion in the guinea-pig: effects of ACE inhibition with perindopril.
Buisson, S; Dalle, M; Dauprat-Dalle, P; Scalbert, E,
)
0.86
"Perindopril treatment reduced cardiac and vascular hypertrophy to different extents in SHR and SHR-SP."( Importance of cardiac, but not vascular, hypertrophy in the cardiac baroreflex deficit in spontaneously hypertensive and stroke-prone rats.
Head, GA; Minami, N, 1992
)
1
"Perindopril treatment had a dose-dependent effect on blood pressure as well as on both structural (media thickness, media: lumen ratio) and functional (estimated pressure against which vessels could contract) parameters of the resistance vessels."( No persistent effect of angiotensin converting enzyme inhibitor treatment in Milan hypertensive rats despite regression of vascular structure.
Andresen, J; Mulvany, MJ; Persson, AE, 1991
)
1
"5. Perindopril treatment diminished noradrenaline-evoked vasoconstrictor responses of aortic rings in both groups, but restored responses in mesenteric arterial beds of vitamin D3/nicotine-treated rats."( Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, protects in vitro carbachol-induced vasorelaxation in a rat model of vascular calcium overload.
Atkinson, J; Capdeville-Atkinson, C; Chillon, JM; Henrion, D; Vinceneux-Feugier, M, 1991
)
1.03
"Perindopril treatment induced a complete control of blood pressure (mean blood pressure from 156 +/- 22 mm Hg in the untreated group to 100 +/- 24 mm Hg in the treated group (P less than .01), compared to 106 +/- 18 mm Hg in the sham group)."( Effects of perindopril on left ventricular hypertrophy, coronary blood flow, and mechanical properties of cardiac muscle in renovascular hypertensive rats.
Besse, P; Bonoron, S; Dallocchio, M; Gosse, P; Grellet, J; Tariosse, L, 1991
)
1.39
"Perindopril treatment alone induced no modification in renal function or structure."( Modulation of gentamicin nephrotoxicity by chronic inhibition of angiotensin-I-converting enzyme in rat.
Borghi, H; Fillastre, JP; Morin, JP; Thomas, N; Toutain, H, 1989
)
1
"Perindopril treatment alone induced no modification in renal function or structure."( [Treatment with an angiotensin converting enzyme inhibitor may increase the nephrotoxicity of gentamicin in rats].
Borghi, H; Fillastre, JP; Morin, JP; Thomas, N; Toutain, H, 1989
)
1
"Treatment with perindopril/amlodipine decreased mean office BP from 163.7/95.4 to 133.6/80.3 mmHg (p < 0.0001), resulting in a hypertension control rate of 69.1%."( Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study.
Fleig, SV; Haller, H; Limbourg, FP; Weger, B, 2018
)
1.06
"Treatment with perindopril was associated with significant improvement of FMVD (6.7 ± 4.1% versus 8.7 ± 5.4% at the end of the study, p<0.05) as well as decrease of blood triglycerides (-18%, p<0.05) and glucose (-9%, p<0.01) with no significant changes of other metabolic parameters. "( [Endothelial and metabolic effects of perindopril in patients with essential hypertension].
Fisun, NI; Nazarov, AG; Nechaeva, GI; Novikov, AI; Pritykina, TV; Semenkin, AA; Zhivilova, LA, 2014
)
1.03
"Treatment with perindopril/β-blocker reduced the relative risk of the primary end point (cardiovascular death, nonfatal myocardial infarction, and resuscitated cardiac arrest) by 24% compared with placebo/β-blocker (HR, 0.76; 95% CI, 0.64-0.91; P = .002)."( Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand, ME; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML, 2015
)
2.2
"Oral treatment with perindopril selectively reduced body fat mass without influencing daily food intake. "( Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats.
Mathai, ML; Naik, S; Sinclair, AJ; Weisinger, HS; Weisinger, RS, 2008
)
0.67
"Treatment with perindopril ameliorated structural changes of diabetic nephropathy and reduced the amount of pimonidazole and ED-1 immunostaining to levels similar to that of controls."( Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats.
Gilbert, RE; Kelly, DJ; Langham, RG; Tiauw, V; Wiggins, KJ; Zhang, Y, 2008
)
2.13
"Treatment of perindopril improves postischemic revascularization."( Molecular mechanism of limbs' postischemic revascularization improved by perindopril in diabetic rats.
Gao, L; Yu, DM, 2008
)
0.93
"Treatment with perindopril/indapamide improves endothelium-dependent vasodilation in comparison with atenolol. "( Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients.
Ghiadoni, L; Kardasz, I; Magagna, A; Salvetti, A; Taddei, S, 2009
)
1.01
"Treatment with perindopril decreased food intake and circulating insulin in both diet groups, and hepatic ACE activity in high fat fed animals only."( Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat.
Cole, TJ; Morris, MJ; Smith, I; Velkoska, E; Warner, FJ, 2010
)
0.7
"Treatment with perindopril reduces progressive LV remodelling that can occur even in the case of small infarct size."( Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study.
Ceconi, C; Chiariello, M; Decarli, A; Ferrari, R; Golcea, S; Nicolosi, GL; Parrinello, G; Remme, WJ; Tavazzi, L, 2009
)
1.08
"Treatment with perindopril dose dependently improved memory by increasing energy metabolism and CBF."( Central angiotensin converting enzyme facilitates memory impairment in intracerebroventricular streptozotocin treated rats.
Hanif, K; Kamat, PK; Najmi, AK; Nath, C; Saxena, G; Tota, S, 2012
)
0.72
"2. treatment with Perindopril significantly protected the function of ECs-dependent relaxation, the Ach-induced relaxation was obviously increased compared with DC."( [Protective effect of perindopril on dysfunction of endothelium-dependent relaxation in diabetic rats].
Chen, X; Liu, SK; You, JL; Zhou, M, 2000
)
0.95
"Treatment with perindopril, an angiotensin converting enzyme inhibitor, ameliorates the neuropathy."( ACE inhibition salvages the visual loss caused by diabetes.
Armitage, JA; Bui, BV; Cooper, ME; Tolcos, M; Vingrys, AJ, 2003
)
0.66
"Pre-treatment with perindopril did not alter the changes in UFR (P=0.63), UcGMP (P=0.46) or UAER (P=0.99) to infusion of ANP, compared with the placebo/ANP arm."( The albuminuric action of atrial natriuretic peptide is not modified by ACE-inhibition with perindopril in Type 2 diabetes.
McDonald, D; McKenna, K; Moore, KB; Thompson, CJ; Tormey, WP, 2003
)
0.86
"Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease."( Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox, KM, 2003
)
1.04
"Treatment of perindopril and bisoprolol could reverse myocardial hypertrophy and changes in DCM rats."( Alteration of endothelin system and calcium handling protein in left ventricles following drug treatment in dilated cardiomyopathy rats.
Chen, XJ; Fang, WW; Geng, Q; Wu, XH; Yang, D; Zhang, JN, 2003
)
0.67
"Pretreatment with perindopril increased bone marrow cellularity and the number of hematopoietic progenitors (granulocyte macrophage colony-forming unit [CFU-GM], erythroid burst-forming unit [BFU-E], and megakaryocyte colony-forming unit [CFU-MK]) from day 7 to 28 after irradiation."( Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells.
Badaoui, S; Charrier, S; Corvol, P; Ezan, E; Giroux, S; Michaud, A; Sainteny, F; Vainchenker, W, 2004
)
0.65
"Treatment with perindopril for 4 days significantly improved platelet responses to sodium nitroprusside; there was also a trend toward a decrease in superoxide radical levels."( Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction.
Chirkov, YY; Holmes, AS; Horowitz, JD; Martelli, JD, 2004
)
1.07
"Treatment with perindopril prevented effectively glomerular hypertrophy and thickening of the GBM."( Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes.
Erensoy, N; Hatemi, H; Oztürk, M; Tunçdemir, M; Uysal, O; Yilmazer, S, 2004
)
0.66
"5. Treatment with perindopril, but not hydrochlorothiazide, resulted in significant increases in SOD-1 and CAT activities and decreases in MDA concentration and Cp oxidase activity."( Effects of perindopril and hydrochlorothiazide on selected indices of oxidative stress in the blood of elderly patients with essential hypertension.
Czuczejko, J; Kedziora, J; Kedziora-Kornatowska, K; Kornatowski, T; Motyl, J; Pawluk, H; Szadujkis-Szadurski, L; Szewczyk-Golec, K, 2006
)
1.05
"The treatment with perindopril decreases blood pressure effectively independent of ACE gene I/D genotype and left ventricular hypertrophy."( [The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril].
Janczak-Bazan, A, 2006
)
0.87
"Cotreatment with perindopril and indapamide increased vascular endothelial growth factor and endothelial nitric-oxide synthase protein contents, two key proangiogenic factors."( Combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats.
Cochain, C; Duriez, M; Lévy, BI; Loinard, C; Mees, B; Silvestre, JS; Vilar, J; You, D, 2008
)
0.92
"Treatment with perindopril reduced sIL-6 levels at pre-exercise by 22% and at 1 and 30 minutes by 30% and 33%, respectively (P<.005)."( Effects of angiotensin-converting enzyme inhibitor therapy on levels of inflammatory markers in response to exercise-induced stress: studies in the metabolic syndrome.
Cheema, FA; Khan, BV; Khan, QA; Rahman, ST; Vaccari, CS, 2008
)
0.69
"Pretreatment with perindopril (0.3 mg/kg daily for six days, n = 7) was compared with no treatment (n = 7)."( Effect of perindopril in pacing-induced canine models of acute and chronic heart failure.
Ogilvie, RI; Zborowska-Sluis, D, 1995
)
1.02
"Treatment with perindopril reversed the changes in cardiac mass and elastic modulus but had no effect on resistance after calcium overload of the elastic arteries."( Aortic stiffness and left ventricular mass in a rat model of isolated systolic hypertension.
Amin, F; Atkinson, J; Makki, T; Niederhoffer, N; Tankosic, P; Tatchum-Talom, R, 1995
)
0.63
"Treatment with perindopril resulted in a significant reduction in polyploidy in the SHRSP, whereas treatment with hydralazine and hydrochlorothiazide had no effect on the percentage of cells in the G2 + M phase of the cell cycle."( The effects of perindopril on vascular smooth muscle polyploidy in stroke-prone spontaneously hypertensive rats.
Campbell, AM; Clark, JS; Davidson, AO; Devlin, AM; Dominiczak, AF; Gordon, JF; Hamilton, CA; Morton, JJ; Reid, JL, 1995
)
0.98
"Treatment with perindopril was free from adverse interactions with the concomitant diseases and therapies."( ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
Adamczak, M; Bachmann, W; Bönner, G; Bretzel, RG; Derichs, R; Krone, W; Lederle, RM; Overlack, A; Reimann, HJ; Zschiedrich, H, 1994
)
0.95
"Treatment with perindopril (3 mg/kg per day) did not affect the blood pressure and plasma AII but inhibited the increase of cardiac weight (P < 0.05)."( The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats.
Higaki, J; Higashimori, K; Mikami, H; Morishita, R; Nagano, M; Nakamura, F; Ogihara, T, 1993
)
0.89
"Treatment with perindopril and either dose of quinapril prevented the development of impaired endothelium-dependent relaxation but had no effect on the response to sodium nitroprusside."( Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats.
Bennett, MA; Thurston, H, 1996
)
0.63
"Treatment with perindopril was well tolerated; only three patients were withdrawn due to side effects and four were withdrawn for other reasons."( Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase.
Anderson, C; Chalmers, J; MacMahon, S; Neal, B; Rodgers, A, 1996
)
0.85
"Treatment with perindopril (4 mg/kg per day for 8 or 12 weeks or either 1 or 4 mg/kg per day for 24 weeks) attenuated the blood pressure rise and prevented stroke."( Prevention of stroke with perindopril treatment in stroke-prone spontaneously hypertensive rats.
Delaney, KH; Kwiecien, JM; Lee, RM; Smeda, JS; Wang, H, 1997
)
0.94
"Treatment with perindopril caused a dose-dependent lowering of blood pressure in SHR during the 10-week treatment. "( Antihypertensive effects of perindopril treatment in adult spontaneously hypertensive rats.
Gillies, L; Lee, RM; Lu, M; Werstiuk, ES, 1997
)
0.94
"Treatment with perindopril was given by gavage every morning beginning at 6 weeks of age."( Prevention of stroke and preservation of the functions of cerebral arteries by treatment with perindopril in stroke-prone spontaneously hypertensive rats.
Lee, RM; Smeda, JS; Wang, H, 1998
)
0.86
"Treatment with perindopril significantly ameliorated the overexpression of osteopontin in association with attenuation of macrophage accumulation."( Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats.
Cox, AJ; Gilbert, RE; Kelly, DJ; Ricardo, SD; Wilkinson-Berka, JL, 2002
)
0.65
"This treatment with perindopril significantly improved survival while electrical stability was comparable between survivors."( The angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs.
Bel, KJ; de Graeff, PA; de Langen, CD; Tobé, TJ; van Gilst, WH; van Wijngaarden, J; Weersink, EG; Wesseling, H, 1992
)
0.86
"Treatment with perindopril greatly reduced intimal proliferation, decreasing the intimal thickness and the collagen content within the intimal layer."( Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection.
Bruneval, P; Michel, JB; Plissonnier, D, 1992
)
1.03
"Treatment with perindopril normalized the systolic and diastolic pressures and completely reversed the artery rigidity markers."( [Effects of chronic inhibition of converting enzymes on the structure and function of the large arterial trunks in rats].
Camilleri, JP; Devissaguet, M; Lévy, BI; Michel, JB; Safar, ME; Salzmann, JL, 1989
)
0.62
"Treatment with perindopril normalized systolic and diastolic blood pressure and completely inverted the markers of rigidity of the large arteries."( Effects of chronic converting enzyme inhibition on the structure and function of large arteries in the rat.
Camilleri, JP; Devissaguet, M; Levy, BI; Michel, JB; Safar, ME; Salzmann, JL, 1989
)
0.62

Toxicity

The study shows that the combination of perindopril and lercanidipine was effective in improving blood pressure in mild essential hypertensive patients. During the study period, 82 adverse events were reported in 52 patients, 40 in the fimasartan group and 42 in the perindobril group.

ExcerptReferenceRelevance
" Sixteen patients withdrew from the study; nine were attributed to adverse events, two in the perindopril group and seven, including one death, in the atenolol group."( Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol.
Anderson, AI; Bartholomeusz, LC; Cameron, DP; Conway, EL; Donnelly, T; Frewin, DB; Hooper, MJ; Louis, WJ; MacDonald, GJ; Morgan, TO, 1992
)
0.77
" The end points include the incidence of progression or improvement in concomitant disease, the incidence of positive or negative interaction between ACE inhibition and concomitant therapy, change in blood pressure, adverse biochemical and hemodynamic reactions, self-reported side effects, and quality of life indices."( Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study.
Overlack, A; Stumpe, KO, 1992
)
0.48
" In a long term study in 632 hypertensive patients 6% of subjects stopped treatment prematurely because of adverse events and cough was the side effect most frequently responsible for treatment withdrawal (1."( The safety and acceptability of perindopril.
Brown, CL, 1990
)
0.56
" Moreover, it does not induce adverse metabolic changes such as hyperglycaemia and/or alterations in the blood lipid profile that could negate the benefits of lowering blood pressure."( Perindopril safety and tolerance in at-risk patients.
Brichard, S; Lambert, AE, 1990
)
1.72
" In this study, 36 patients interrupted the treatment prematurily because of an adverse reaction (5."( [First intention treatment of arterial hypertension. Effectiveness and safety of perindopril].
Bizot-Espiard, JG; Brown, C; Santoni, JP, 1989
)
0.5
"Angiotensin converting enzyme inhibitors (ACEIs) constitute a safe and effective therapeutic class for the treatment of hypertension."( Tolerance and safety of perindopril.
Brown, C; Castaings, C; Pouyollon, F; Richard, C; Santoni, JP, 1989
)
0.58
" Treatment with perindopril was free from adverse interactions with the concomitant diseases and therapies."( ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
Adamczak, M; Bachmann, W; Bönner, G; Bretzel, RG; Derichs, R; Krone, W; Lederle, RM; Overlack, A; Reimann, HJ; Zschiedrich, H, 1994
)
0.96
" Adverse event rates (including hypokalemia) were similarly low in both groups."( Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension.
Castaigne, A; Chalmers, J; Chastang, C; Feldmann, L; Guez, D; Morgan, T, 1999
)
0.56
" Selection of effective and safe antihypertensive therapy for these individuals is an important health-care priority."( Safety profile of perindopril.
Clark, LT, 2001
)
0.64
" Specialist heart failure nurse supervision of ACE inhibitor titration during the in-hospital stay could be a safe and effective means of avoiding this problem."( Specialist nurse supervised in-hospital titration to target dose ACE inhibitor--is it safe and feasible in a community heart failure population?
Ledwidge, M; McDonald, K; Ryder, M; Timmons, L; Travers, B, 2003
)
0.32
"Specialist heart failure nurse supervised initiation and rapid in-hospital titration of ACE inhibitor to at least target dose is feasible and safe in a severe heart failure population admitted with class IV heart failure."( Specialist nurse supervised in-hospital titration to target dose ACE inhibitor--is it safe and feasible in a community heart failure population?
Ledwidge, M; McDonald, K; Ryder, M; Timmons, L; Travers, B, 2003
)
0.32
" Adverse events and withdrawals were not significantly different between perindopril-indapamide, placebo, or routine antihypertensive drugs."( A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.
An, N; Kang, S; Ren, M; Wu, YF, 2004
)
0.78
" The incidence of adverse events was significantly higher in the perindopril plus diuretic combination therapy group than in the perindopril monotherapy group."( Efficacy and safety of diuretics in combination with perindopril in hypertensive stroke patients: Results of the Japan Perindopril and Diuretics on Cerebrovascular Disease Study (J-PADOC).
Hasegawa, Y; Shimada, K; Yamaguchi, T, 2010
)
0.85
" The treatment efficacy and the incidence of adverse events were evaluated at the end of 4, 8 and 12 weeks after treatment initiation."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.7
" Four adverse events were observed in group A, while seven and nineteen adverse events occurred in group B and in group C, respectively."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.7
"Although its results were collected in an overall limited number of patients in a single center, this study shows that the combination of perindopril and lercanidipine, compared with lercanidipine alone or perindopril alone, was effective in improving blood pressure in mild essential hypertensive patients, and also decreased the incidence of adverse events."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.9
"0001), and a lower incidence of pedal edema and adverse events compared with amlodipine."( Efficacy and safety of perindopril arginine + amlodipine in hypertension.
Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015
)
0.73
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43
" The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43
" Both treatment regimens were well tolerated regarding adverse events or laboratory testing."( Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial.
Amodeo, C; Asmar, R; Brzozowska-Villatte, R; de Champvallins, M; Mourad, JJ, 2017
)
0.71
" Adverse reactions were reported by only 13 (0."( Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice
Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017
)
0.69
" A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension."( Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation.
Bistrika, EA; Elliott, WJ, 2018
)
2.12
"Incremental uptitration with dosage-adapted perindopril/amlodipine SPC is a safe and effective strategy for managing hypertension."( Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension.
Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019
)
1
" During the study period, 82 adverse events were reported in 52 patients, 40 in the fimasartan group and 42 in the perindopril group (P = 0."( A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patien
Chae, SC; Choi, YJ; Chun, KJ; Ihm, SH; Jeon, ES; Jeong, JO; Kim, CH; Kim, EJ; Kim, KI; Kim, MH; Kim, SH; Kim, SJ; Kim, SY; Lee, HY; Lee, SY; Park, S; Park, YH; Pyun, WB; Rhee, MY; Shin, J; Sohn, IS; Song, JM; Sung, KC; Yoo, KD, 2021
)
1.02
" Despite their efficacy in reducing the morbidity and mortality of individuals with breast cancer, the use of these agents is limited by adverse cardiotoxic side effects."( Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.
Aukema, HM; Austria, JA; Bortoluzzi, T; Cheung, DYC; Christie, S; Eastman, S; Eekhoudt, CR; Jassal, DS; Mittal, I; Ravandi, A; Singal, PK; Thliveris, J; Varghese, SS, 2022
)
1.03

Pharmacokinetics

Plasma concentrations of perindoprilat are increased and renal clearance reduced in elderly subjects. The pharmacokinetic and pharmacodynamic responses to enalapril, perindobril and cilazapril have been studied in essential hypertensives.

ExcerptReferenceRelevance
" Pharmacokinetic and pharmacodynamic parameters were estimated for 96 h after the first dose and after 4-week once-daily treatment."( Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects.
Conway, EL; Drummer, O; Harris, G; Jarrott, B; Louis, WJ; McNeil, JJ; Rowley, K; Workman, BS; Worland, P, 1992
)
0.52
" The pharmacokinetic parameters of perindopril, perindoprilat and perindoprilat glucuronide were evaluated after single administration to healthy volunteers (N = 12) of 8 mg of perindopril tert-butylamine salt by oral route (treatment A), by intravenous route (bolus in 5 min, treatment B) and of an equimolar dose of perindoprilat (6."( Pharmacokinetics of perindopril and its metabolites in healthy volunteers.
Ammoury, N; Devissaguet, JP; Devissaguet, M; Perret, L, 1990
)
0.88
" Maximal pharmacodynamic effects (ACE inhibition, increase in plasma renin activity and angiotensin I, reduction in aldosterone and angiotensin II and blood pressure) are seen 4 to 6 hours after dosing, with substantial effects still present at 24 hours."( Perindopril. A review of its pharmacokinetics and clinical pharmacology.
Lees, KR; Macfadyen, RJ; Reid, JL, 1990
)
1.72
" Plasma concentrations of perindoprilat are increased and renal clearance reduced in elderly subjects, resulting in an increase in the acute pharmacodynamic effect of perindopril."( Pharmacokinetics of perindopril: therapeutic consequences.
Hughes, DM; Lees, KR; McNeill, CA; Reid, JL, 1989
)
0.9
" Plasma concentrations of perindoprilat are increased and renal clearance reduced in elderly subjects, resulting in an increase in the acute pharmacodynamic effect of perindopril."( Pharmacokinetics of perindopril: therapeutic consequences.
Hughes, DM; Lees, KR; McNeill, CA; Reid, JL, 1989
)
0.9
" Cmax and AUC tended to be higher after the 4 mg dose in the Chinese group who had a lower body weight than the Caucasians."( Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.
Anderson, PJ; Critchley, JA; Resplandy, G; Tomlinson, B, 1995
)
0.52
"36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237."( Digoxin pharmacokinetics and perindopril in heart failure patients.
Desche, P; Dews, IM; Resplandy, G; Robinson, J; Stephens, JD; Vandenburg, MJ, 1993
)
0.58
"The purpose of the present report was to develop a pharmacokinetic model for perindoprilat based on three phase I studies including administration of oral and intravenous perindopril and administration of intravenous perindoprilat."( The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state.
Aarons, L; Parker, E; Resplandy, G; Rowland, M, 2005
)
0.86
"To determine whether a potential pharmacokinetic interaction exists between perindopril arginine 5 mg and amlodipine 5 mg, after administration as a fixed-combination of perindopril 5 mg/amlodipine 5 mg (S05985)."( Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers.
Chen, X; Hu, P; Jiang, J; Liu, T; Zheng, X, 2016
)
0.9
" Serial blood samples were collected in each treatment period for determination of plasma amlodipine, perindopril, and perindoprilat concentrations and for calculation of the respective pharmacokinetic parameters (AUC(0-∞), AUC(0-t), C(max), and t(max))."( Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers.
Chen, X; Hu, P; Jiang, J; Liu, T; Zheng, X, 2016
)
0.89
" Objective The aim of this prospective study was to evaluate the prevalence of noncompliance with perindopril therapy in adult out-patients using pharmacokinetic simulations."( Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation.
Čabala, R; Marešová, V; Šálek, T; Šíma, M; Slanař, O; Vodička, M, 2017
)
1.03
"To investigate the pharmacokinetic parameters of perindopril and perindoprilat in healthy volunteers, a simple and sensitive UPLC-MS/MS method with isotope-labeled internal standards of perindopril-d4 and perindoprilat-d4 was established and further applied in a bioequivalence study."( A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement
.
Cai, H; Gu, Y; Guo, J; He, B; Huang, X; Liu, X; Tan, X; Wei, W; Yang, H; Yin, Y; Zhang, B; Zhou, X, 2020
)
1.08
" 20 healthy Chinese subjects (16 males and 4 females) were enrolled and had their plasma concentrations of perindopril and perindoprilat quantified and calculated for the pharmacokinetic parameters."( A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement
.
Cai, H; Gu, Y; Guo, J; He, B; Huang, X; Liu, X; Tan, X; Wei, W; Yang, H; Yin, Y; Zhang, B; Zhou, X, 2020
)
1.04
" A lack of pharmacokinetic and pharmacodynamic (PK/PD) studies in older patients makes specific and tailored advices towards antihypertensive drug therapy difficult."( DiffErenCes in AntihypertenSive Drug Blood Levels in Patients with HypertensiON (DECISION): Protocol for a Prospective Observational Study Comparing Pharmacokinetics and Pharmacodynamics Between Young and Elderly Patients.
Hassan, D; Koch, BCP; Peeters, LEJ; Versmissen, J, 2022
)
0.72

Compound-Compound Interactions

ivabradine in combination with perindopril versus metoprolol has a more favorable effect on circulatory resistance and blood flow velocity in the brachiocephalic arteries of patients with CHD and AH.

ExcerptReferenceRelevance
"To explore the interaction of low-dosage aspirin combined with angiotensin-converting enzyme (ACE) inhibitors by prostacyclin (PGI2), thromboxone A2 (TXA2) and norepinephrine (NE)) levels in rabbits' blood."( [Effect of low-dosage aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in rabbits' blood].
Fang, YX; Li, J; Zhuang, HP, 2002
)
0.58
" The ratio of PGI2 to TXA2 increased, and NE levels decreased significantly during the administration of aspirin combined with ACE inhibitors."( [Effect of low-dosage aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in rabbits' blood].
Fang, YX; Li, J; Zhuang, HP, 2002
)
0.58
"MDC of HF remains cost-beneficial when combined with optimal, medical care."( Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?
Barry, M; Cahill, J; Ledwidge, M; Maurer, B; McDonald, K; Ryan, E; Ryder, M; Timmons, L; Travers, B, 2003
)
0.32
"The primary objective was to assess the effects of rilmenidine monotherapy and in combination with perindopril on blood pressure (BP) in patients assessed with grade 1 or 2 essential hypertension."( Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).
Borbás, S; Dienes, BS; Farsang, C; Lengyel, M; Zorándi, A, 2003
)
0.78
"To explore the interactive effect of low-dosage aspirin (ASA) combined with perindopril (PER), on prostacyclin (PGI2), thromboxone A2 (TXA2), and norepinephrine (NE) in the blood of arteriosclerosis rabbit models and the cardiac function."( [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function].
Li, J; Liu, LH; Zhuang, HP, 2003
)
0.83
"The ratio of PGI2 to TXA2 increased, and the NE levels decreased significantly; meanwhile, the heart rate decreased and the cardiac function improved during the administration of aspirin combined with perindopril in arteriosclerosis rabbit models."( [Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function].
Li, J; Liu, LH; Zhuang, HP, 2003
)
0.79
"We investigated bone marrow stromal cell (BMSC) transplantation combined with angiotensin-converting enzyme inhibitor (ACEI) treatment in acute myocardial infarction (AMI) and the role of insulin-like growth factor-1 (IGF-1)."( Bone marrow stromal cell transplantation combined with angiotensin-converting enzyme inhibitor treatment in rat with acute myocardial infarction and the role of insulin-like growth factor-1.
Hu, YZ; Huang, YL; Kuang, J; Mai, WY; Qiu, RF; Song, YB, 2012
)
0.38
"To investigate the effects of ivabradine in combination with perindopril on cerebral blood flow and endothelial functional activity."( [Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril].
Gapon, LI; Kolesnikova, SN; Musikhina, NA; Petelina, TI; Utesheva, AB, 2012
)
0.81
" Group 1 (n = 38) patients took ivabradine in combination with perindopril and Group 2 (n = 26) received metoprolol."( [Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril].
Gapon, LI; Kolesnikova, SN; Musikhina, NA; Petelina, TI; Utesheva, AB, 2012
)
0.81
"By unidirectionally affecting the vasomotor function of the endothelium, ivabradine in combination with perindopril versus metoprolol has a more favorable effect on circulatory resistance and blood flow velocity in the brachiocephalic arteries of patients with CHD and AH."( [Cerebral blood flow and endothelial functional activity in patients with coronary heart disease and arterial hypertension during therapy with ivabradine in combination with perindopril].
Gapon, LI; Kolesnikova, SN; Musikhina, NA; Petelina, TI; Utesheva, AB, 2012
)
0.79
"Thus, despite the similar BP reduction the combination of ACE-inhibitor--perindopril with indapamide retard possesses more favorable vascular and metabolic effects compared to combination with hydrochlorothiazide that potentially may account for different prognosis of patients with arterial hypertension on long-term treatment."( [Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide].
Chindareva, OI; Nechaeva, GI; Pritykina, TV; Semenkin, AA; Stroeva, TV; Zhenatov, AB; Zhivilova, LA, 2014
)
0.88
"The aim of this study was to evaluate the effects of perindopril or barnidipine alone or combined with simvastatin on metabolic parameters and hepatic steatosis degree."( Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015
)
2.11
"This experiment aimed to study the effect of trimetazidine combined with perindopril on NT-proBNP levels in rats with dilated cardiomyopathy (DCM)."( Effect of trimetazidine combined with perindopril on NT-proBNP level in rats with dilated cardiomyopathy.
Chen, L; Lin, J; Yan, J; Zhong, B, 2020
)
1.06
"Conclusion      Patients with IHD and AH in combination with early CKD have pronounced impairment of the condition of arterial blood vessels and the heart."( [Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting].
Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV, 2021
)
0.62
"The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs)."( Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.
Brzozowska-Villatte, R; Chalmers, J; De Champvallins, M; Mancia, G; Mourad, JJ, 2023
)
1.34
"Across medium to high cardiovascular risk population, long-term indapamide, mostly combined with perindopril-based treatment, provided evidence of benefit on mortality and morbidity."( Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.
Brzozowska-Villatte, R; Chalmers, J; De Champvallins, M; Mancia, G; Mourad, JJ, 2023
)
1.37

Bioavailability

Perindopril is rapidly absorbed with an oral bioavailability of 95% and is mainly eliminated by metabolic processes.

ExcerptReferenceRelevance
"Food has been shown to reduce the bioavailability of the angiotensin-converting enzyme inhibitor captopril, but not the bioavailability of inhibitors administered as ester prodrugs."( Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum.
Devissaguet, M; Ferry, A; Funck-Brentano, C; Gardin, ME; Jaillon, P; Lecocq, B; Lecocq, V, 1990
)
0.54
" Perindopril is rapidly absorbed with an oral bioavailability of 95% and is mainly eliminated by metabolic processes."( Pharmacokinetics of perindopril and its metabolites in healthy volunteers.
Ammoury, N; Devissaguet, JP; Devissaguet, M; Perret, L, 1990
)
1.51
" Its bioavailability is greater than 70% and is not influenced by meals."( Clinical review of perindopril in the treatment of hypertension.
Antony, I; Lerebours, G, 1994
)
0.62
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability and bioequivalence studies."( High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study.
Kandikere, VN; Komarneni, P; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006
)
0.61
"Angiotensin-converting enzyme (ACE) inhibitors differ in their lipophilic/hydrophilic index that determines their tissue bioavailability and affinity to ACE, which may result in major differences in the degree of blockade of cardiac ACE."( Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE".
Coletta, E; Davies, R; Haddad, H; Leenen, FH; Ruzicka, M; White, R, 2010
)
0.36
"The present study was performed to compare the bioavailability of two perindopril erbumine (CAS 107133-36-8) 4 mg tablet formulations (test formulation and reference formulation)."( Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers.
Arland, JA; Deniati, SH; Handayani, LR; Lian, LY; Santoso, ID; Setiawati, A; Setiawati, E; Yunaidi, DA, 2011
)
0.9
" The aim of this study was to estimate the influence of hypotensive drugs (angiotensine converting enzyme inhibitors (ACE-I), β-blockers, Ca-antagonists, diuretics) on the potential bioavailability of magnesium, iron, zinc and copper from buckwheat groats in vitro enzymatic digestion."( The influence of selected hypotensive drugs on the bioavailability of minerals from buckwheat groats in vitro enzymatic digestion.
Bogdański, P; Chiniewicz, B; Suliburska, J,
)
0.13

Dosage Studied

Perindopril inhibited the brain ACE activities by more than 50%. Imidapril and enalapril showed much less potent effects. Patients received a daily oral dosage of either 4 to 8 mg of perindoprill or 40 to 80 mg of nifedipine.

ExcerptRelevanceReference
" Patients received a daily oral dosage of either 4 to 8 mg of perindopril or 40 to 80 mg of nifedipine in slow-release form."( Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine.
Gotzen, R; Lenz, T; Liederwald, K; Meyer-Sabellek, W; Schulte, KL; van Gemmeren, D, 1992
)
0.73
" We suggest that liver cirrhosis may be associated with imparied deesterification of perindopril to its active metabolite perindoprilat but that no dosage adjustment of perindopril is required in cirrhotic patients."( The pharmacokinetics of perindopril in patients with liver cirrhosis.
Funck-Brentano, C; Grangé, JD; Jaillon, P; Midavaine, M; Resplandy, G; Thiollet, M, 1992
)
0.81
"The excretions of urinary sodium, potassium, magnesium, urate, and water after dosing with diuretics or the angiotensin-converting enzyme inhibitor perindopril are reported, as well as the results of other recent studies."( Effects of angiotensin-converting enzyme inhibitors on urinary excretions: interactions with diuretics.
Leary, WP; Reyes, AJ; Van der Byl, K, 1992
)
0.48
" 8 In view of the important influence of renal impairment on the elimination and action of the active substance perindoprilat, a dosage reduction of perindopril is proposed in in patients with renal failure."( Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
De Broe, ME; Genissel, PM; Thomas, JR; Verpooten, GA, 1991
)
0.78
" The patients were treated for 3 months with monthly assessments, "uncontrolled" patients (DBP greater than 90 mm Hg) had their dosage doubled and then, if necessary, atenolol 50 mg was added."( A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension.
Andrejak, M; Carré, A; Deruyttere, M; Gotzen, R; Magometschnigg, D; Santoni, JP; Stumpe, KO, 1991
)
0.57
" Perindopril alone tended to reduce serum and urinary thromboxane B2 (TxB2) and to raise urinary 6-ketoPGF1 alpha and PGE2 and inhibited serum ACE activity 24 h post dosing by about 85%."( Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.
Abdel-Haq, B; Favilla, S; Magagna, A; Salvetti, A, 1991
)
1.45
" As it has been shown that the kinetics of perindoprilat are mainly affected by renal insufficiency, a dosage reduction is therefore recommended on initiation of treatment in elderly patients and in those with renal failure according to the degree of renal failure."( Pharmacokinetics of perindopril in high-risk populations.
Genissel, P; Resplandy, G, 1991
)
0.87
" Perindopril was administered at a dosage of 2 or 4 mg according to initial systolic blood pressure and efficacy was evaluated at 1 and 3 months according to the NYHA classification, a score of clinical severity, the duration of two exercise stress tests on a bicycle ergometer or treadmill and the cardiothoracic ratio."( [Perindopril and chronic heart failure].
Bounhoure, JP, 1991
)
2.1
" In contrast, maximal ACE inhibition is observed 4-6 hours after oral dosing and substantial inhibition persists beyond 24 hours."( Clinical pharmacology of perindopril.
Lees, KR, 1990
)
0.58
" During repeated dosing there is little accumulation of drug, and no evidence of increased haemodynamic effect after chronic treatment in hypertensives."( Pharmacokinetics of perindopril: therapeutic consequences.
Hughes, DM; Lees, KR; McNeill, CA; Reid, JL, 1989
)
0.6
" The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)."( [Perindopril: first-line treatment of arterial hypertension].
Desche, P; Zanchetti, A, 1989
)
1.19
" The other half of 8 weeks long hypertensive rats (G3) were treated during 8 weeks with Perindopril in drinking water at a dosage adjusted to maintain blood pressure (BP) measured with tail cuff method under 140 mmHg."( [Effects of perindopril on left ventricular hypertrophy, coronary reserve and mechanical properties of the papillary muscle of the rat with renovascular arterial hypertension].
Besse, P; Bonoron, S; Dallocchio, M; Gosse, P; Grellet, J; Tariosse, L, 1987
)
0.87
" Glucuronidase hydrolysis of urine obtained from rats dosed with either enalapril, ramipril or perindopril indicated the absence of glucuronidate conjugates of these inhibitors in rat urine."( Biotransformation studies of di-acid angiotensin converting enzyme inhibitors.
Drummer, OH; Kourtis, S, 1987
)
0.49
" the effect of the drug at the end of the 24-hour dosage period."( [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study].
Fedelesová, V; Uhlír, O; Widimský, J, 1995
)
0.56
" If office diastolic pressure was greater than or equal to 90 mm Hg after 4 weeks, the dosage was doubled and continued for another 4 weeks."( Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.
Lamote, J; Sennesael, J; Tasse, S; Verbeelen, D; Violet, I, 1995
)
0.65
" Subjects (diastolic blood pressure > or = 100 and < or = 120 mm Hg) were randomly assigned to treatment for 12 months with either perindopril (n = 13, 4 to 8 mg/d) or atenolol (n = 12, 50 to 100 mg/d); the dosage was adjusted upward and in some cases combined (n = 5, perindopril; n = 2, atenolol) with thiazide diuretic to achieve target blood pressure (diastolic blood pressure below 90 mm Hg)."( Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.
Aalkjaer, C; Cooper, A; Heagerty, AM; Mulvany, MJ; Stephens, N; Thybo, NK, 1995
)
0.5
" Perindopril was administered at a dosage of 2 to 8 mg once daily for 12 weeks."( Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance.
Azukizawa, S; Kaneko, M; Kigoshi, T; Matsui, A; Morimoto, S; Nakano, S; Uchida, K,
)
1.43
" Oral dosing with active drugs led to different temporal responses."( Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
Lees, KR; MacFadyen, RJ; Reid, JL; Squire, IB, 1993
)
0.29
" The dose-response curve flattened after 8 mg per day, and there was no difference in arterial pressure reduction or in the percentage of responders between once- and twice-daily administration of perindopril."( Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group.
Barden, PL; Chrysant, SG; McDonald, RH; Weiss, RJ; Wright, JT, 1993
)
1.92
"To examine the dose-response characteristics of perindopril at the time of its peak and trough antihypertensive effects, with the primary outcome measure being changes in diastolic blood pressure."( A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group.
Myers, MG, 1996
)
0.85
" The patients then crossed over to the other time of dosage and the measurements were repeated."( The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night.
Anderson, A; Jones, E; Morgan, T, 1997
)
0.52
" The spectrophotometric and atomic absorption spectrometric procedures hold their accuracy and precision well when applied to the determination of ramipril and perindopril dosage forms."( Spectrophotometric and atomic absorption spectrometric determination of ramipril and perindopril through ternary complex formation with eosin and Cu(II).
Abdellatef, HE; Ayad, MM; Taha, EA, 1999
)
0.72
" This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders."( Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension.
Castaigne, A; Chalmers, J; Chastang, C; Feldmann, L; Guez, D; Morgan, T, 1999
)
0.56
"Perindopril 4-8 mg day-1 causes a persistent decrease in BP during the 24 h dosing interval, which is mostly maintained over the 24-48 h after dosing."( Persistence of anti-hypertensive effect after missed dose of perindopril.
Leenen, FH; Tan, KW, 1999
)
1.99
" Treatment with indapamide alone at this dosage did not significantly influence most responses but in combination with perindopril it strengthened the effect of perindopril."( The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats.
Cicutti, N; Guez, D; Maurin, A; Rakusan, K; Schiavi, P, 2000
)
0.52
"There was a linear dose-response relationship (P<0."( Fixed low-dose combination therapy in hypertension--a dose response study of perindopril and indapamide.
Asmar, R; Leenen, FH; Myers, MG; Safar, M, 2000
)
0.54
" Acute dose-response curves were constructed for AII and norepinephrine (NE)."( Renin-angiotensin system in two genetically normotensive strains of Lyon rats.
Lantelme, P; Lo, M; Sassard, J, 2000
)
0.31
" BPs were measured in the morning, 20-25 h after the previous day's dose (ie, at the end of the dosing interval)."( Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly.
Leenen, FH; McNally, CF; Tanner, J, 2000
)
0.56
" In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm HG: Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months)."( Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria.
Allen, TJ; Campbell, DJ; Cooper, ME; Gilbert, RE; Hammond, JJ; Jerums, G; Raffaele, J; Tsalamandris, C, 2001
)
0.6
"A new sensitive, simple, rapid and precise reversed-phase high performance liquid chromatographic (HPLC) and two spectrophotometric methods have been developed for resolving binary mixture of perindopril and indapamide in the pharmaceutical dosage forms."( Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations.
Erk, N, 2001
)
0.73
" Studies comparing this dosage of perindopril/ indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined."( Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.
Cheer, SM; Goa, KL; Matheson, AJ, 2001
)
2.03
" Studies in which BP has been monitored for 24-hour intervals show that perindopril (1) has a gradual onset of action, (2) provides smooth BP control over its once-daily dosing interval, (3) has a trough-peak ratio of about 1, and (4) maintains its antihypertensive efficacy despite missed doses."( Efficacy of perindopril in the treatment of systemic hypertension.
Oparil, S, 2001
)
0.92
" Perindoprilat is cleared renally; dosage should be adjusted in patients with renal impairment."( Dosage considerations with perindopril for systemic hypertension.
Sica, DA, 2001
)
1.52
" Tolerability, drug interactions, and dosage and administration of the drug are reviewed."( Perindopril.
Chu, VL; O'Loughlin, DC; Singh, D,
)
1.57
"2 mg/kg per d perindopril was the lowest dosage to largely prevent severe diabetic nephropathy in transgenic Ren-2 rats."( Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.
Cooper, ME; Kelly, DJ; Mifsud, SA; Skinner, SL; Wilkinson-Berka, JL, 2002
)
0.94
"24 mg/kg/day) or each component given alone at the same dosage for 3 and 28 days."( Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs.
Clergue, M; Duriez, M; Kamsu-Kom, N; Lévy, BI; Silvestre, JS, 2002
)
0.55
" Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol."( Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Asmar, R; Battegay, E; Chamontin, B; De Leeuw, PW; Duprez, D; Hitzenberger, G; Mallion, JM; O'Brien, E; O'Rourke, MF; Rahn, KH; Romero, R; Safar, ME, 2004
)
0.56
" A 1-week washout period was observed between dosing periods."( Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction.
Lees, K; Muir, S; Shah, I; Walters, M, 2004
)
0.73
" Dosing with perindopril did not affect resting cerebral blood flow velocity (percent change from baseline +3."( Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction.
Lees, K; Muir, S; Shah, I; Walters, M, 2004
)
1.1
" After 6 weeks the dosage was either maintained (group I) or increased to 8 mg/day (group II) based on the physician's assessment of blood pressure (BP) response."( Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
Batchelor, A; Cohn, JN; Guo, W; Julius, S; Lagast, H; Neutel, JM; Shen, Y; Turlapaty, P; Weber, MA, 2004
)
0.63
" Brain hexamethyl propylene amino oxide single photon emission computed tomography (SPECT) was performed before dosing and at estimated time of peak drug effect (6-8 h after first dose)."( Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial.
Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR, 2005
)
0.73
"In this 1-year multicentre randomized double-blind study, patients received an increasing dosage of perindopril/indapamide (n = 284) or enalapril (n = 272)."( Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.
Dahlöf, B; De Leeuw, PW; de Simone, G; Degaute, JP; Dubourg, O; García-Puig, J; Gosse, P; Guéret, P; Karpov, Y; Magometschnigg, D; Matos, L; Schmieder, R, 2005
)
1.99
" It was concluded that losartan and perindopril similarly alter taste sensitivity during repeated dosing of the drugs."( Comparative study of taste disturbance by losartan and perindopril in healthy volunteers.
Araki, N; Fujimura, A; Ioka, T; Sugimoto, K; Tsuruoka, S; Wakaumi, M, 2005
)
0.85
"Sixty-six patients with chronic heart failure were randomly divided into 2 groups: low-dose group, treated by perindopril with the dosage of 2 mg/d initially and gradually increased up to 2-4 mg/d, and high-dose group, treated by perindopril with the dosage of 2 mg/d initially and gradually increased up to 8 approximately 10 mg/d."( [Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure].
Deng, B; Luo, M; Song, HM; Zhang, J, 2005
)
0.54
" The method has been successfully applied to the determination of perindopril in commercial dosage forms."( Optimized and validated initial-rate method for the determination of perindopril erbumine in tablets.
Anwar, N; Kashif, M; Rahman, N, 2006
)
0.81
" Once daily dosing of the preparation provided high level of compliance of patients with treatment."( [Effect of twelve-month combined therapy with perindopril and indapamide on the level of blood pressure and left ventricular hypertrophy in patients with hypertensive disease].
Alekhin, MN; Chumakova, OS; Larina, VN; Sidorenko, BA; Timofeeva, LA; Ugriumov, MO, 2006
)
0.59
" The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance."( Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse, P, 2006
)
1.78
" Study of the effect of dosage and peculiarities of peridopril appears to be the most important taking into account age factor that has been insufficiently studied."( [Effect of perindopril on indices of cardiac function and quality of life in patients with arterial hypertension in regard to age].
Dzhanaridze, LU; Mamaladze, GT; Megreladze, II; Pagava, ZT; Sadunishvili, MZ, 2006
)
0.72
"25 mg with decreases in mean 24-h ambulatory BP from 24 to 48 h and 48 to 72 h after dosing being -11."( The impact of one or two missed doses on the duration of action of combined perindopril and indapamide.
Leenen, FH; Myers, MG, 2007
)
0.57
"625 mg with reductions in mean 24-h blood pressure from 24-48 h and 48-72 h after dosing being -11."( Persistence of the antihypertensive effect of low-dose combination therapy in mild hypertension.
Leenen, FH; Myers, MG, 2006
)
0.33
" At the revised dosage (perindopril arginine 5-10 mg/day corresponds to perindopril-tert-butylamine 4-8 mg/day), the new salt is equivalent in terms of pharmacokinetics, efficacy, safety, and acceptability."( Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril.
Telejko, E, 2007
)
2.09
" Patients were followed up monthly for 3 months and the dosage of perindopril could be increased to 10 mg/day in cases of failure to achieve BP control."( Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study.
Ionescu, DD, 2009
)
0.88
" Using the same dosing regimen, only perindopril inhibited the brain ACE activities by more than 50%, whereas imidapril and enalapril showed much less potent effects."( Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease.
Kanda, T; Nagata, Y; Shirakura, S; Suzuki, N; Takahashi, S; Takayama, M; Uchida, S; Yamada, K, 2010
)
0.87
" After a 4-week placebo period, 94 and 107 patients with uncomplicated hypertension were randomly assigned to treatment with atenolol (AT) at dosage of 50 mg per day or perindopril/indapamide (PER/IND) at dosage of 2/0."( Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs.
Dolan, E; Jin, Y; Li, Y; O'Brien, E; Protogerou, A; Richart, T; Safar, ME; Staessen, JA; Thijs, L; Wang, JG, 2011
)
0.56
" Uptitration to the full therapeutic dosage of perindopril is an efficient approach for the management of a broad range of hypertensive patients without CAD."( Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study.
Anand, S; Tsoukas, G; Yang, K, 2011
)
0.87
"This paper describes the development and validation of a microemulsion liquid chromatography (MELC) method for simultaneous determination of perindopril tert-butylamine and its impurities in bulk active substances and the pharmaceutical dosage form of tablets."( Validation of an oil-in-water microemulsion liquid chromatography method for analysis of perindopril tert-butylamine and its impurities.
Dotsikas, Y; Ivanović, D; Jancić-Stojanović, B; Malenović, A; Masković, M; Medenica, M,
)
0.55
" Dosage could be increased to 10/2."( Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
Pella, D, 2011
)
0.6
" Using the same dosing regimen, perindopril inhibited the brain ACE activities of rats more than imidapril or enalapril."( Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats.
Horita, T; Kanda, T; Nagata, Y; Suzuki, N; Takaba, K; Takahashi, S; Takayama, M; Yamada, K, 2011
)
0.89
" The preparation was prescribed in different fixed dosage depending on duration of hypertension, quantity of taken hypertension groups of preparations and blood pressure level."( [Estimation of antihypertension efficiency and use of fixed combination perindopril+amlodipin by uncontrollable hypertension patients within the limits of routine treatment].
Ishmurzin, GP, 2011
)
0.6
" At inclusion, previous angiotensin-converting enzyme (ACE) inhibitors and/or calcium channel blockers (CCBs) were replaced by a perindopril/amlodipine fixed-dose combination at a dosage (5/5, 5/10, 10/5, or 10/10 mg) chosen by the physician and uptitrated at month 1, if required."( Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination.
Nagy, VL, 2013
)
0.84
"A specific, stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the estimation of perindopril erbumine (PDE) in tablet dosage form."( Stability-indicating RP-HPLC method for the quantitative analysis of perindopril erbumine in tablet dosage form.
Dugga, HH; Nayakanti, D; Peraman, R, 2014
)
0.84
" The extending range of various fixed combinations as well as new pharmaceutical dosage forms, including the newly introduced orodispersible tablets of perindopril, enables optimization of treatment for every patient, an increase in the patients treatment adherence, and also improvement in longterm blood pressure control with a consequent effect on reduction of morbidity and mortality."( [Perindopril in the treatment of hypertension and cardiovascular diseases: evolution continues with the orodispersible dosage form].
Václavík, J, 2013
)
1.5
" The developed method is applicable for the determination of related substances in bulk drugs and simultaneous assay in a tablet pharmaceutical dosage form."( A validated stability-indicating RP-LC method for the simultaneous determination of amlodipine and perindopril in tablet dosage form and their stress degradation behavior under ICH-recommended stress conditions.
Gumustas, M; Ozkan, SA,
)
0.35
" Perindopril/indapamide dosage could be increased, from 5/1."( Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.
Gorbat, TV; Netchessova, TA; Shepelkevich, AP, 2014
)
1.62
" In comparative trials, telmisartan treatment resulted in significantly higher reduction in trough BP and mean ambulatory diastolic BP for the last 8 hours of the dosing interval compared with perindopril."( Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
Chwallek, F; Pimenta, E; Wang, JG, 2014
)
0.81
"A novel stability indicating gradient reverse-phased high-performance liquid chromatographic method has been developed for the quantification of impurities of perindopril tert-butylamine (PER) in pharmaceutical dosage form."( Simultaneous quantification of related substances of perindopril tert-butylamine using a novel stability indicating liquid chromatographic method.
Gagyi, L; Kis, EL; Réti, ZZ; Sipos, E; Szabó, ZI, 2015
)
0.86
" The patients were treated with a fixed combination of dosage forms ofp erindopril and amlodipine at 10/5 mg/days or 10/10 mg/days for 24 weeks."( [Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension].
Budagovskaia, ZM; Iskenderov, BG; Sisina, ON, 2013
)
0.65
" Commercially available tablet formulations were successfully analysed using the developed methods without interference from other dosage form additives except PLS model, which failed to determine both drugs in their pharmaceutical dosage form."( Conventional univariate versus multivariate spectrophotometric assisted techniques for simultaneous determination of perindopril arginin and amlodipine besylate in presence of their degradation products.
Abbas, SS; Essam, HM; Hegazy, MA; Zaazaa, HE, 2015
)
0.63
" The lack of a classic dose-response function likely results from either nonspecific effects of perindopril or from between-group differences that were not accounted for in the current study (i."( Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.
De La Garza, R; Grasing, K; Haile, CN; Kosten, TR; Newton, TF; Verrico, CD, 2016
)
0.88
"Between March 2011 and January 2015, 85 patients were randomised, 79 completed both dosing times, 78 completed the CPAP phase."( Chronotherapy for hypertension in obstructive sleep apnoea (CHOSA): a randomised, double-blind, placebo-controlled crossover trial.
Arima, H; Cistulli, PA; Grunstein, RR; Phillips, CL; Serinel, Y; Wong, KH; Yee, BJ, 2017
)
0.46
" The primary objective of the PETRA study was to evaluate the efficacy of blood pressure (BP) control with once daily administration of the different dosage strengths of the once-daily, triple fixed combination of perindopril, indapamide, and amlodipine."( The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study.
Ábrahám, G; Dézsi, CA, 2017
)
0.88
"Significant increases in BP control were observed with each dosage increment of perindopril/amlodipine, which was well tolerated, rising from 21% (3."( Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension.
Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019
)
0.97
" Oral dosing of perindopril for 4 weeks concomitant with TAA could mend the altered parameters near to normal values and abolished the ongoing fibrosis extension."( Targeting AngII/AT1R signaling pathway by perindopril inhibits ongoing liver fibrosis in rat.
Abd El-Rahman, SS; Fayed, HM, 2019
)
1.12
"5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification."( Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019
)
0.75
" Le diagnostic a été posé a posteriori et le dosage des activités des enzymes du catabolisme des kinines - aminopeptidase P (APP), carboxypeptidase N (CPN) et enzyme de conversion de l’angiotensine (ECA) - a démontré une diminution des activités APP et ECA."( [ACE-inhibition and bradykinin-mediated angioedema].
De Kock, M; Defendi, F; Ndjekembo Shango, D; Simonet, O; Vallot, F, 2020
)
0.56
" Perindopril, which has been used in the clinical practice for more than 25 years, is a long-acting lipophilic angiotensin-converting enzyme inhibitor with a once-daily dosage schedule and a high affinity to tissue-converting enzyme."( Perindopril: a long-term certainty in treating hypertension.
Souček, M, 2021
)
2.97
"Comparative study of different spectrophotometric approaches used for the simultaneous determination of perindopril, indapamide, and amlodipine in bulk powder and in dosage form Triplixam."( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data.
Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023
)
1.12
"The methods were applied for the analysis of the mixture in the pharmaceutical dosage form Triplixam and in vitro release at intestinal pH (7."( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data.
Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023
)
0.91
"Antihypertensives bisoprolol fumarate (BIS) and perindopril arginine (PER) were simultaneously determined in their pure, bulk, and combined tablet dosage form."( Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.
Almalki, MA; Binsaleh, AY; Mahmoud, OA; Mohamed, MA; Omran, AA, 2023
)
1.4
" A content uniformity test demonstrated that the drugs in their dosage form met the acceptance limit (85-115%)."( Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.
Almalki, MA; Binsaleh, AY; Mahmoud, OA; Mohamed, MA; Omran, AA, 2023
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitorAn EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
alpha-amino acid esterThe amino acid ester derivative obtained the formal condensation of an alpha-amino acid with an alcohol.
dicarboxylic acid monoesterA monoester of a dicarboxylic acid.
organic heterobicyclic compound
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Perindopril Action Pathway35

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency4.46680.044717.8581100.0000AID485294
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.71220.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.49150.003041.611522,387.1992AID1159553
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.67170.000229.305416,493.5996AID743075
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
IDH1Homo sapiens (human)Potency32.64270.005210.865235.4813AID686970
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.33320.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.00150.00010.533610.0000AID780571
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID679609TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.1 uM, Perindopril: 50 uM) in MDR1-expressing LLC-PK1 cells2002Life sciences, Feb-15, Volume: 70, Issue:13
Interaction of digoxin with antihypertensive drugs via MDR1.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID780571Inhibition of ACE (unknown origin)2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Perindopril and ramipril phosphonate analogues as a new class of angiotensin converting enzyme inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,713)

TimeframeStudies, This Drug (%)All Drugs %
pre-199089 (5.20)18.7374
1990's369 (21.54)18.2507
2000's704 (41.10)29.6817
2010's449 (26.21)24.3611
2020's102 (5.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.39 (24.57)
Research Supply Index7.78 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index185.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (100.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials556 (30.40%)5.53%
Reviews198 (10.83%)6.00%
Case Studies55 (3.01%)4.05%
Observational36 (1.97%)0.25%
Other984 (53.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (72)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension [NCT03747978]Phase 430 participants (Actual)Interventional2016-10-01Completed
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension- [NCT01101009]Phase 4486 participants (Actual)Interventional2010-04-30Completed
The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial [NCT01219413]Phase 416 participants (Actual)Interventional2009-03-31Completed
DescripTion of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/atoRvastatin/Perindopril sinGle Pill Combination trEatmenT in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET) [NCT05764317]400 participants (Anticipated)Observational2023-04-30Not yet recruiting
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. [NCT03502031]Phase 472 participants (Anticipated)Interventional2018-10-01Recruiting
"Multinational Observational Uncontrolled Open Programme The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy" [NCT03722524]1,247 participants (Actual)Observational2018-10-01Completed
Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy [NCT01583114]Phase 36 participants (Actual)Interventional2011-12-31Terminated(stopped due to recruitement problem)
ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy. [NCT01089452]Phase 40 participants (Actual)InterventionalWithdrawn(stopped due to Study not started due to administrative reasons.)
Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease [NCT02299310]Phase 460 participants (Anticipated)Interventional2014-11-30Not yet recruiting
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. [NCT03921736]Phase 4180 participants (Actual)Interventional2000-01-10Completed
Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial [NCT01295047]Phase 418 participants (Actual)Interventional2006-07-31Completed
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India [NCT05683301]Phase 41,968 participants (Anticipated)Interventional2022-08-30Recruiting
Pharmacogenomics Of Hypertension: A New Approach For A Personalized Medicine [NCT03249285]Phase 3300 participants (Anticipated)Interventional2016-03-31Recruiting
A Randomized, Double-blind, Active-controlled, 2-parallel Group, Optional Titration, Multicenter, Phase 3b Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without Diuretics Combination in Elderly Patients Wi [NCT03246555]Phase 3241 participants (Actual)Interventional2016-07-15Completed
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia, 8 Weeks, Phase 3, Randomized, Double-blind, Active-control, Multinational, Multi-center, Parallel Study [NCT04591808]Phase 3146 participants (Actual)Interventional2021-09-09Terminated(stopped due to for strategic reasons)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]Phase 310,000 participants (Anticipated)Interventional2016-04-11Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Rationale and Design of a Simple Randomized Trial Evaluating Losartan and Perindopril in Blacks Type 2 Diabetics Patients: the Cardiac and Renal Protection With Losartan or Perindopril (CARE-PLP) Trial [NCT04222686]Phase 423 participants (Actual)Interventional2017-12-20Completed
Influence of Single Nucleotide Polymorphisms of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects: A Phase II, Multicenter, Double-blind Study [NCT02777489]Phase 2140 participants (Actual)Interventional2016-02-18Terminated(stopped due to Unproven hypothesis)
Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans [NCT02742467]Phase 4702 participants (Actual)Interventional2017-06-07Completed
A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications [NCT01016886]Phase 1/Phase 299 participants (Actual)Interventional2010-09-30Active, not recruiting
Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension [NCT02655029]2,285 participants (Actual)Observational [Patient Registry]2015-11-25Completed
An Evaluation of the Effect of an Angiotensin-converting Enzyme (ACE) Inhibitor on the Growth Rate of Small Abdominal Aortic Aneurysms. [NCT01118520]Phase 2224 participants (Actual)Interventional2011-09-30Completed
A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension [NCT00461903]Phase 3316 participants (Actual)Interventional2007-12-31Completed
The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients [NCT02085265]Phase 2150 participants (Anticipated)Interventional2014-03-31Recruiting
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]Phase 42,400 participants (Anticipated)Interventional2016-02-29Recruiting
A Phase II Open Label Pilot Study of the Angiotensin-converting Enzyme Inhibitor, Perindopril, in Pediatric Cancer Survivors With Evidence of Early Cardiac Remodelling or Dysfunction. [NCT01948232]Phase 20 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to no participants enrolled)
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation [NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study [NCT00202553]Phase 250 participants (Anticipated)Interventional2003-07-31Completed
Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months [NCT00202592]Phase 250 participants (Anticipated)Interventional2003-11-30Completed
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril Erbumine/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg Tablets (Pharmtechnology LLC, Republic of Belarus) and Triplixam® 10 mg/2.5 mg/10 mg Tablets (L [NCT05940909]Phase 150 participants (Anticipated)Interventional2023-06-24Recruiting
Precision Treatment Based on Genetic Information Associated With Response to Angiotensin Converting Enzyme Inhibitor [NCT05535595]Phase 477 participants (Actual)Interventional2019-11-06Completed
To Develop and Implement a Method for Medical Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer [NCT04588935]Phase 2100 participants (Actual)Interventional2019-07-01Completed
Bioequivalence Study of Fasting Oral Perindopril Tert-butylamine Tablets in Healthy Subjects With a Single-dose, Randomized, Open, Two-cycle, Crossover Trial Design [NCT04556058]Phase 132 participants (Actual)Interventional2018-11-29Completed
Evaluation of Carotid Intima Media Thickness by Treatment of Vascular and Metabolic Factors With Combined Antihypertensive and Hypolipidemic Therapy [NCT04306627]Phase 4200 participants (Anticipated)Interventional2020-04-15Not yet recruiting
Perindopril vs Ramipril for Persistence in MAU Reduction Study [NCT02729441]Phase 323 participants (Actual)Interventional2010-04-30Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fasting Conditions [NCT01012687]48 participants (Actual)Interventional2007-04-30Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions [NCT01013155]48 participants (Actual)Interventional2007-05-31Completed
Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial) [NCT02710552]Phase 4100 participants (Anticipated)Interventional2016-04-30Not yet recruiting
Effects of Combined Ventricular Unloading and Pharmacological Therapy on Left Ventricular Metabolic Dysfunction in Heart Failure [NCT00402376]Phase 420 participants (Anticipated)Interventional2007-04-30Terminated
Rationale and Design of a Simple Randomized Trial Evaluating Comparative Effects of Perindopril and Zofenopril in Blacks Hypertensive Patients: Short Term Effects on Cardiac and Oxidative Status With Perindopril or Zofenopril (PEZO-HP) Trial [NCT04254042]Phase 424 participants (Actual)Interventional2018-10-01Completed
Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial) [NCT02710539]Phase 4100 participants (Anticipated)Interventional2016-04-30Not yet recruiting
Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE) [NCT03730116]1,909 participants (Actual)Observational2018-11-14Completed
"Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Test Product PERINDOPRES® TRIO, 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide/ 10 mg Amlodipine Tablets (PrJSC Pharmaceutical Firm [NCT05470764]Phase 152 participants (Actual)Interventional2021-05-30Completed
The Hypertension in the Very Elderly Trial (HYVET) [NCT00122811]Phase 44,000 participants (Anticipated)Interventional2000-11-30Active, not recruiting
The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. [NCT00485368]Phase 317 participants (Actual)Interventional2004-01-31Completed
IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs [NCT00128518]Phase 4139 participants (Actual)Interventional2004-10-31Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]Phase 4291 participants (Actual)Interventional2015-06-01Completed
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension [NCT03295734]Phase 2213 participants (Anticipated)Interventional2018-05-29Recruiting
Bioequivalence Study of Oral Perindopril Tert-butylamine Tablets After Meal in Healthy Subjects With a Single-dose, Randomized, Open-lable, Four-cycle, Crossover Trial Design [NCT04556110]Phase 132 participants (Actual)Interventional2018-11-20Completed
Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial [NCT02213224]Phase 4180 participants (Anticipated)Interventional2014-08-31Recruiting
Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure [NCT00292162]41 participants (Actual)Interventional2007-01-31Completed
Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition [NCT01682577]18 participants (Actual)Interventional2008-09-30Completed
Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes [NCT03393715]Phase 420 participants (Actual)Interventional2016-02-29Completed
Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial [NCT01819441]Phase 41,200 participants (Anticipated)Interventional2012-05-31Recruiting
A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC) [NCT02651415]Phase 212 participants (Actual)Interventional2016-08-31Completed
Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypert [NCT02449811]107 participants (Actual)Observational2015-04-30Completed
One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease: An Open Label, Randomized, Multicenter Study [NCT04148820]Phase 4100 participants (Anticipated)Interventional2019-11-01Not yet recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
DOXAZOSIN AS A TREATMENT FOR POST TRAUMATIC STRESS SYNDROME [NCT02308202]Phase 130 participants (Actual)Interventional2012-01-31Completed
Multimodal Intervention to Reduce Cardiovascular Risk Among Hypertensive Older Adults [NCT01891513]104 participants (Actual)Observational2014-01-31Completed
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study [NCT03047538]Phase 40 participants (Actual)Interventional2017-09-01Withdrawn(stopped due to Insufficient funds)
An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence [NCT01062451]Phase 180 participants (Actual)Interventional2009-05-31Completed
Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients [NCT01575652]Phase 443 participants (Actual)Interventional2008-06-30Completed
Early Treatment of ARNI on Myocardial Remodeling and Progress in Patients With Post-AMI (EARLYmyo-CRPⅠ) [NCT04342351]Phase 4280 participants (Anticipated)Interventional2020-05-01Not yet recruiting
"Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Test Product PERINDOPRES® DUO, 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide Tablets (PrJSC Pharmaceutical Firm Darnitsa) and Refer [NCT05464745]Phase 142 participants (Actual)Interventional2021-05-19Completed
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopr [NCT01556997]Phase 3837 participants (Actual)Interventional2012-02-29Completed
Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients [NCT02995954]Phase 4100 participants (Actual)Interventional2014-01-31Completed
Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors [NCT00915928]47 participants (Actual)Interventional2009-07-31Terminated(stopped due to No effect of the ACE inhibitor evaluated halfway in the study)
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. A Multicentre [NCT05288400]Phase 3150 participants (Actual)Interventional2018-05-14Completed
Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome [NCT04023565]Phase 4120 participants (Anticipated)Interventional2019-03-11Recruiting
Perindopril+Bisoprolol in Therapy of Patients With Atrial Fibrilation [NCT04484688]50 participants (Anticipated)Observational2020-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00292162 (6) [back to overview]Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%
NCT00292162 (6) [back to overview]Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP) at Baseline
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP) at 6 Months
NCT00292162 (6) [back to overview]Plasma B-type Natriuretic Peptide (BNP)
NCT00292162 (6) [back to overview]Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months
NCT00915928 (1) [back to overview]Size of Chronic Subdural Hematoma (CSDH)
NCT01118520 (2) [back to overview]Change in the Growth Rate of Abdominal Aortic Aneurysm
NCT01118520 (2) [back to overview]Number of Participants With Aneurysm Related Death
NCT01556997 (2) [back to overview]Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).
NCT01556997 (2) [back to overview]Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).
NCT01669434 (6) [back to overview]Postoperative Hypertension
NCT01669434 (6) [back to overview]Postoperative Hypotension
NCT01669434 (6) [back to overview]Acute Renal Failure
NCT01669434 (6) [back to overview]Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]Number of Participants With Interoperative Hypotension
NCT01669434 (6) [back to overview]Older Age Subgroup
NCT02651415 (6) [back to overview]Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
NCT02651415 (6) [back to overview]Median Time to Progression Free Survival (PFS)
NCT02651415 (6) [back to overview]Number of Participants That Have Any Grade HFSR Toxicity
NCT02651415 (6) [back to overview]Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
NCT02651415 (6) [back to overview]The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
NCT02651415 (6) [back to overview]The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril
NCT03722524 (5) [back to overview]The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline
NCT03730116 (6) [back to overview]The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline
NCT03730116 (6) [back to overview]Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS
NCT03730116 (6) [back to overview]Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice
NCT03730116 (6) [back to overview]Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks
NCT03730116 (6) [back to overview]Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels
NCT03730116 (6) [back to overview]Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position

Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%

left ventricular ejection fraction (LVEF) is a measure of the % of blood ejected from the ventricle in one heart beat. It is a measure of cardiac function. We measured LVEF at baseline and at 6 months, to assess whether there had been a change in the patients cardiac function over time. (NCT00292162)
Timeframe: baseline and 6 months

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy2.8
Radiofrequency Ablation4.5

[back to top]

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)in % (NCT00292162)
Timeframe: Baseline

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy43
Radiofrequency Ablation36

[back to top]

Plasma B-type Natriuretic Peptide (BNP) at Baseline

Plasma B-type Natriuretic Peptide (BNP) measured at basline (NCT00292162)
Timeframe: Baseline

Interventionpicograms per millilitre (Mean)
Medical Therapy1846
Radiofrequency Ablation2550

[back to top]

Plasma B-type Natriuretic Peptide (BNP) at 6 Months

Plasma B-type Natriuretic Peptide (BNP) (NCT00292162)
Timeframe: 6 months

Interventionpicograms per millilitre (Mean)
Medical Therapy1931
Radiofrequency Ablation2354

[back to top]

Plasma B-type Natriuretic Peptide (BNP)

venous blood taken to assess levels of the above peptide. High evels of the peptide are associated with adverse prognosis. Blood levels are taken at baseline and 6 months. The change over 6 months is assessed, thereore it is possible to have a negative number if the level falls. (NCT00292162)
Timeframe: baseline and 6 months

Interventionpicograms per millilitre (Mean)
Medical Therapy85
Radiofrequency Ablation-196

[back to top]

Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months

Left Ventricular Ejection Fraction as measured by Magnetic Resonance Imaging (MRI)at 6 months (NCT00292162)
Timeframe: 6 months

Interventionpercentage of blood ejected in one beat (Mean)
Medical Therapy46
Radiofrequency Ablation41

[back to top]

Size of Chronic Subdural Hematoma (CSDH)

Volume of CSDH remnant three months after evacuation measure using xyz/2 on CT scans (NCT00915928)
Timeframe: 3 months

Interventioncm^3 (Mean)
ACE Inhibitor28.4
Placebo22.8

[back to top]

Change in the Growth Rate of Abdominal Aortic Aneurysm

Aneurysm growth rate over 2 years, estimated from the sequential AAA diameter measurements (external diameter measured in the longitudinal plane). (NCT01118520)
Timeframe: Annual rate over the entire period of 24 month

Interventionmm (Least Squares Mean)
Perindopril1.77
Amlodipine1.81
Placebo1.66

[back to top] [back to top]

Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Systolic Blood Pressure (SBP).

(NCT01556997)
Timeframe: Day 0 to Day 42

InterventionmmHg (Mean)
XOMA 985-23.4
Amlodipine Besylate (AMLb)-19.6
Perindopril Erbumine (PERe)-13.4

[back to top]

Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).

(NCT01556997)
Timeframe: Day 0 to Day 42

InterventionmmHg (Mean)
XOMA 985-15.7
Amlodipine Besylate (AMLb)-13.2
Perindopril Erbumine (PERe)-9.5

[back to top]

Postoperative Hypertension

Any systolic blood pressure greater than 180 mmHg. (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission33
ACEI Continuation17

[back to top]

Postoperative Hypotension

Any systolic blood pressure less than 90 mmHg (NCT01669434)
Timeframe: Arrival in PACU to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission15
ACEI Continuation31

[back to top]

Acute Renal Failure

Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level (NCT01669434)
Timeframe: Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.

InterventionParticipants (Count of Participants)
ACEI Omission6
ACEI Continuation10

[back to top]

Low Blood Pressure Subgroup

Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg. (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission4
ACEI Continuation2

[back to top]

Number of Participants With Interoperative Hypotension

Number of Participants with Interoperative Hypotension (systolic blood pressure under 80 mmHg) (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission76
ACEI Continuation95

[back to top]

Older Age Subgroup

Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg (NCT01669434)
Timeframe: During anesthesia, an expected average of 3 hours.

InterventionParticipants (Count of Participants)
ACEI Omission48
ACEI Continuation49

[back to top]

Median Time Course to Development of Worst Grade (Grade 3) HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

Median time course for participants to develop worst grade 3 HFSR toxicity is defined as the time (days) from start date of study drug to date of first documented grade 3 HFSR toxicity and will be calculated only for patients who had a HFSR toxicity grade 3. (NCT02651415)
Timeframe: p to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

Interventiondays (Median)
Single Arm Trial12

[back to top]

Median Time to Progression Free Survival (PFS)

Median time (in months) to PFS. PFS is defined as the time from start date of study drugs to the date of first documented disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. PFS will be evaluated based on RECIST v1.1 criteria, 20% progression or any new lesion. (NCT02651415)
Timeframe: From start date of study drugs to the date of first documented disease progression or death due to any cause.

InterventionMonths (Median)
Single Arm Trial2.60

[back to top]

Number of Participants That Have Any Grade HFSR Toxicity

"The trial will measure the toxicities of HFSR in participants receiving both perindopril and regorafenib using the CTCAE v4.03 criteria.~The toxicity of HFSR will be expressed based on the number of participants in the study (N=10) who are experiencing HFSR of all grades." (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

InterventionParticipants (Count of Participants)
Single Arm Trial7

[back to top]

Number of Participants With Maximal Severity of HFSR as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

The number of participants that experienced an HFSR of grade 3 or above as assessed by CTCAE v4.03 criteria when treated with a combination of regorafenib and perindopril. (NCT02651415)
Timeframe: Up to Safety Follow-Up Visit (30 days +/- 7 days after permanently stopping study treatment)

InterventionParticipants (Count of Participants)
Single Arm Trial5

[back to top]

The Number of Participants That Experienced All Grade Toxicities as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

All grades of adverse events (including HFSR) will be evaluated using CTCAE v4.03, at baseline and at D1 of each cycle while they are on the study drug and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: At baseline and at D1 of each cycle while on the study drug and during the 30-day follow-up period

Interventionparticipants (Number)
Single Arm Trial10

[back to top]

The Number of Participants That Experienced Any Grade of Hypertension as Assessed by CTCAE v4.03 Criteria When Treated With a Combination of Regorafenib and Perindopril

All grades of hypertension will be evaluated using CTCAE v4.03, weekly for the first six weeks while they are on the study drug, then every second week and during the 30-day follow-up period (Post therapy). (NCT02651415)
Timeframe: Weekly for the first six weeks while on the study drug, then every second week and during the 30-day follow-up period

InterventionParticipants (Count of Participants)
Single Arm Trial6

[back to top]

The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.

Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension14.34

[back to top]

The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the SF-36 survey Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension23.57

[back to top]

The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline

Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded. (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension33.47

[back to top]

The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension13.64

[back to top]

Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline

The assessment of the target office BP levels (SBP <140 mm Hg and DBP <90 mm Hg) was performed in accordance with ESC Guidelines for the management of arterial hypertension (2013) (NCT03722524)
Timeframe: Baseline, 3 months

Interventionpercentage of patients (Number)
Patients With Arterial Hypertension93.38

[back to top]

The Mean SBP Changes (mm Hg) at the Visit 3 vs. Baseline

Changes in the mean office systolic BP levels (in mm Hg) in the sitting position (NCT03730116)
Timeframe: 3 months

Interventionmm Hg (Mean)
Mean of SBP Changes31.5

[back to top]

Impact on the Quality of Life of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: VAS

Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC (NCT03730116)
Timeframe: 3 month

Interventionunits on a scale - mm (Mean)
the Patients With HT and Concomitant Stable CAD35.1

[back to top]

Good and Moderate Adherence to Bisoprolol/Perindopril FDC Therapy in Patients With HT and Stable CAD in Everyday Practice

"Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer No to all questions: good compliance; Answer Yes to 1-2 questions: minor compliance; Answer Yes to 3 or more questions: noncompliance)" (NCT03730116)
Timeframe: 3 month

InterventionParticipants (Count of Participants)
the Patients With HT and Concomitant Stable CAD1827

[back to top]

Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice: # of Angina Attacks

Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC (NCT03730116)
Timeframe: 3 month

Interventionnumber of angina attacks per week (Mean)
the Patients With HT and Concomitant Stable CAD-3.2

[back to top]

Efficacy of Bisoprolol/Perindopril FDC in Patients With HT and Stable CAD in Everyday Practice Regarding the BP: % of Patients Achieving Target Levels

The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP < 140 mm Hg and DBP < 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC (NCT03730116)
Timeframe: 3 month

InterventionParticipants (Count of Participants)
the Patients With HT and Concomitant Stable CAD1640

[back to top]

Changes in the Mean Office Diastolic BP Levels (in mm Hg) in the Sitting Position

Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC (NCT03730116)
Timeframe: 3 months

Interventionmm Hg (Mean)
Mean Office DBP Changes Between v3 vs Baseline15.9

[back to top]